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CHAPTER I 
 
INTRODUCTION: MALARIA DIAGNOSTICS IN THE MODERN WORLD 
 
 In 2000, the United Nations made a set of Millennium Development Goals (MDGs) to 
guide an international partnership to reduce extreme poverty worldwide by 2015.1 One of the 
targets of the MDGs was focused on halting and reversing the incidence of malaria by 2015, 
which has been met.2 The World Health Organization (WHO) estimates that between 2000 and 
2015, malaria incidence has decreased by 37% and malaria death rates have decreased by 60%. 
Furthermore, in 2000 malaria was the leading cause of death for children under 5 in sub-Saharan 
Africa, but by 2015 it was fourth. While this is certainly progress, malaria remains endemic in 91 
countries in Africa, Asia, and the Americas3 (Figure 1.13). The World Health Organization  
 
 
Figure 1.1.3 Map showing worldwide prevalence of malaria in 2016 compared to 2000. 
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estimates that there were 214 million malaria cases and 438,000 malaria deaths in 2015, with 
roughly 88% of these cases and deaths occurring in sub-Saharan Africa, followed by Southeast 
Asia. It is clear that while progress is being made towards malaria elimination, this disease still 
remains a major health concern in tropical regions of the world.  
 
Biology of the Malaria Parasite 
 Malaria in humans is caused by the Plasmodium parasite, transmitted by Anopheles 
mosquitos. There over 100 Plasmodium species, but only four species are known to cause 
malaria in humans, with a fifth species beginning to infect humans as well. The others infect 
various other mammals, birds, and even reptiles. The main species causing human malaria are P. 
falciparum, P. vivax, P. ovale, and P. malariae.4 P. falciparum is the predominant species in 
Africa, though it is found in subtropical and tropical areas worldwide. It is also one of the most 
virulent malaria species. P. vivax is most common in Asia and Latin America, though it is found 
in some areas of Africa. This species, along with P. ovale, has a dormant liver stage as part of its 
life cycle, which can cause relapses months or years after the initial illness if not treated 
effectively. P. ovale is very similar to P. vivax but is found mostly in West Africa and the 
Western Pacific islands. P. malariae is found worldwide, and can cause lifelong chronic 
infection and kidney disease if left untreated.5  
 A malaria parasite infects two hosts, humans and female Anopheles mosquitos, during its 
full lifecycle (Figure 1.26). When an infected female Anopheles mosquito bites a human and 
takes a blood meal, she also injects Plasmodium sporozoites into the human’s bloodstream. 
These sporozoites infect the liver, where they can mature into schizonts, rupture, and release 
merozoites. This liver stage can last for several days or a few weeks, and results in a delay 
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between the mosquito bite and the development of symptoms. P. vivax and P. ovale sporozoites 
can also become dormant hypnozoites in the liver, and can re-activate to complete their lifecycle 
weeks, months, or years after the initial mosquito bite.7 Once merozoites are released, they infect 
red blood cells and become trophozoites, also known as the ring stage. The trophozoites mature 
into schizonts that rupture, releasing merozoites again. This asexual replication is known as the 
erythrocytic cycle, and it is responsible for producing the symptoms of the disease.  Trophozoites 
in the blood stage can also become gametocytes, which are ingested by a female Anopheles 
mosquito that bites an infected human. In the stomach of the mosquito, the gametocytes undergo 
sexual reproduction and generate zygotes, which mature into elongated, motile ookinetes. The 
ookinetes develop into oocysts after invading the wall of the mosquito midgut, and the oocysts 
grow until they rupture and release sporozoites. The sporozoites then travel to the mosquito 
salivary glands, where they can be injected into another human host and continue the 
transmission cycle.8 
 
 
Figure 1.2.6 Simplified life cycle of the malaria parasite. 
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 Understanding this parasite biology is necessary to effectively diagnose, treat, and 
ultimately eliminate the transmission of malaria. Because malaria is caused by a parasite, there 
are many biomarkers available to diagnose its presence. The parasite itself can be a biomarker 
when analyzing blood via microscopy, and any proteins or DNA sequences produced by the 
parasite but not by humans can be used as biomarkers as well. In order to use these biomarkers 
most effectively, however, we must understand how the parasite, its protein expression levels, 
and its DNA concentrations change during the course of its lifecycle. We must also understand 
how the body deals with these biomarkers after the infection has been cleared. For example, 
several countries have reported gene deletions in P. falciparum for the protein biomarker 
PfHRP2. In these regions, it would be inappropriate to use a PfHRP2 test for the detection of P. 
falciparum. In regions where PfHRP2 is a common biomarker, the protein has been shown to 
persist in a patient’s blood for several weeks after parasite clearance.9 This indicates that PfHRP2 
should not be used to monitor treatment effectiveness. Malaria diagnostics will have to account 
for these biological realities and others as the global community moves toward the WHO goal of 
malaria elimination. 
 
Current Malaria Diagnostic Landscape 
To guide the work of malaria elimination campaigns through 2030, the World Health 
Organization has released a new Global Technical Strategy (GTS) for Malaria.10 As mentioned 
above, malaria is currently endemic in 95 countries. The WHO sets goals in the Global Technical 
Strategy to eliminate malaria from at least 10 of these countries by 2020, and at least 35 of these 
countries by 2030. Several of these countries are within five years of reaching their goal of 
malaria elimination, defined as zero new locally-transmitted infections in a geographical area. In 
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order to actually achieve the goals set out by WHO, the GTS outlines three “pillars” for future 
action. The first pillar is to “ensure universal access to malaria prevention, diagnosis, and 
treatment” and this is to be supported with expanded research in these areas as well.10 While 
preventing and treating malaria are obvious steps toward elimination, the utility of diagnostic 
tests are not always apparent, even to those in the malaria community. 
The most apparent reason for the need for diagnostic tests for malaria lies in the fact that 
malaria shares its main symptoms of fatigue, nausea, joint pain, and fever with many other 
diseases.11 Therefore, diagnostics are necessary to determine the particular illness for a patient 
presenting with fever so that the patient can receive accurate and timely treatment. If a patient is 
incorrectly diagnosed with malaria based on clinical symptoms alone, they will be given 
antimalarial drugs that will not treat their actual illness, delaying effective treatment and 
allowing that illness to possibly become more serious. Diagnostic tests are also important for 
patients that do have malaria, because they help determine the most effective treatment available. 
P. falciparum and P. vivax may be treated with different combinations of drugs, because the liver 
stage hypnozoites of P. vivax must also be eliminated, so it is important to determine the species 
of infection.7 P. falciparum resistance to the drug artemisinin has been documented in five 
counties in Southeast Asia, and the responsible gene mutation has been recently discovered.3,12,13 
There are no point-of-care tests for this mutation, but they will be necessary in the future for 
accurate treatment. Like P. falciparum, P. vivax has also developed resistance to certain drugs in 
certain areas, so treatment may change depending on the geographical area where the infection 
was acquired.11 
The diagnosis of P. vivax malaria in general is expected to become more important as P. 
falciparum transmission is eliminated.14 Most current malaria control efforts are focused on sub-
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Saharan Africa, where P. falciparum is most present and causes the most deaths, but P. vivax is 
most prevalent in Southeast Asia and South America, where it is estimated to have caused 13.8 
million cases of malaria in 2015.2 Currently, rapid diagnostic tests that detect P. vivax lack the 
sensitivity, stability, and availability of those that detect P. falciparum.14–16 This is especially 
important to address because P. vivax infections tend to show low parasitemia in comparison to 
P. falciparum infections.7,16 There are also currently no diagnostic tests to detect the presence of 
hypnozoites in a patient’s liver, which would be extremely helpful to monitor treatment and 
prevent relapses of P. vivax. Currently, the only “radical cure” drug for P. vivax that kills blood 
stage parasites as well as hypnozoites is primaquine, but yet another diagnostic is needed in this 
case to determine if the drug is safe to use for each individual patient.7 Primaquine causes severe, 
often fatal, hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) 
deficiency, which is a common genetic abnormality ranging from 3 to 30% frequency in tropical 
areas.17 Tests for G6PD deficiency require complex procedures and are expensive, so often a 
patient’s G6PD status is unknown. In these cases, the risk of administering primaquine must be 
balanced with the benefit of eliminating the risk of relapse. A point-of-care G6PD test will 
ultimately be necessary to control and eliminate P. vivax. 
 As the world moves towards malaria elimination, it will become imperative to diagnose 
low parasitemia infections of all malaria species. Especially in low-transmission areas, it is quite 
common for people to be infected with low-density parasitemia that does not produce symptoms 
and is undetectable with typical field diagnostic tests.10,14 These asymptomatic individuals can 
still transmit the disease to mosquitos, however, and unknowingly contribute to sustaining the 
parasite by acting as a disease reservoir.11,18,19 There is debate about the parasitemia cut-off 
between asymptomatic and symptomatic infections, but it is generally accepted that 
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asymptomatic infections occur at parasite densities of 200 p/µL or less. This threshold can vary 
by individual, however, partly due to immunological differences in infected individuals, and 
partly due to the complexities of the parasite lifecycle. While high parasitemia generally 
correlates with disease severity, the densities of circulating parasites and sequestered parasites 
can change depending on the lifecycle stage of the parasites and their synchronicity.20 Even 
though asymptomatic infections are by definition difficult to diagnose, it is necessary to diagnose 
and treat these infections in order to reach the goal of malaria elimination. 
 
 
Figure 1.3. Various malaria diagnostic techniques. 
 
 Current diagnostics detect malaria parasites using proteins, nucleic acids, or the parasite 
itself as biomarkers (Figure 1.3). The current “gold standard” diagnostic technique is 
microscopy, where a stained blood sample is examined under a microscope to count the parasites 
present. Microscopy is a much more accessible diagnostic technique than PCR, because even 
small rural health clinics can often afford a small microscope, slides, and stain. However, 
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technical expertise is still required for an accurate diagnosis, so the necessary training for 
clinicians can increase the overall cost of the test. This technique also has a variable limit of 
detection due to its dependence on the skill of the microscopist. The most sensitive diagnostic 
technique available is polymerase chain reaction (PCR), which can detect DNA from parasite 
densities of 1 p/µL or less, depending on the assay. While this limit of detection is ideal for 
diagnosing asymptomatic infections, the technique is not ideal for most settings. PCR is an 
expensive, time-consuming technique that requires great technological expertise to perform 
correctly. This means that PCR is most often reserved for research laboratories or large, regional 
hospitals, and it is not commonly used at the point of care. To overcome these technical and 
monetary obstacles, rapid diagnostic tests (RDTs) were developed in the 1990s as an accessible 
diagnostic technique for the point of care. These tests detect parasite proteins, and have a 
variable limit of detection depending on the manufacturer and the particular biomarker protein. 
Despite this variability, RDTs have become one of the most widely-used diagnostic tests for 
malaria due to their portability, ease of use, and relatively low cost.  
 Protein-based RDTs fill a need and have many advantages for malaria diagnostics at the 
point of care, but they also come with disadvantages. RDTs typically detect either PfHRP2, a 
protein specific to P. falciparum, or pLDH, a protein found in all malaria species, or a 
combination of the two. This means that RDTs can aid in determining the species of infection for 
a patient, but only to a degree. If the patient is tested using a multiplex test, it can determine if 
the infection is P. falciparum or non-falciparum, but all P. vivax, P. malariae, and P. ovale 
infections will be grouped together as non-falciparum. If the test only detects one protein, it can 
provide even more limited information. For example, a negative result with a PfHRP2 test could 
mean that the patient does not have malaria at all, or that the patient is infected with a non-
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falciparum species. Results from multiplex tests are further complicated because pLDH tests 
tend to be less sensitive and have higher limits of detection than PfHRP2 tests. This introduces 
uncertainty in test results, along with past manufacturing issues that caused certain RDT brands 
to perform much worse than other brands. There is still a place for protein-based malaria 
diagnostics, but it is clear that there are continuing issues to address in order to make these tests 
reliable and informative at the point of care. 
 In comparison to protein, DNA can provide clinicians with much more diagnostically 
relevant information. Multiplex PCR assays have been developed to detect every species of 
malaria infecting humans, which eliminates the uncertainty of a positive pLDH test result.21–23 
Sequence-specific DNA tests can also be used to test for G6PD deficiency24 and genes which 
confer drug resistance13, both important problems that have been unaddressed by current 
diagnostics. Furthermore, PCR has been used to detect malaria DNA in patient saliva several 
times, which is promising for DNA diagnostics as non-invasive tests that do not require a blood 
sample.22,25–27 However, as mentioned above, DNA diagnostic tests are currently limited in their 
reliance on PCR amplification because DNA is typically present in samples in very low 
concentrations. DNA tests hold high potential for malaria diagnostics, but the gap between high-
resource hospital laboratories and low-resource health clinics must be bridged in order to make 
DNA analysis a robust, accessible diagnostic option for the point of care. 
 
Scope of this work 
 The current diagnostics listed above must be improved, and new diagnostics must be 
developed, in order to meet the challenges for malaria elimination described above. Current 
protein-based RDTs must be improved or redesigned in order to lower the limit of detection. 
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DNA-based diagnostics can be used to test for species of infection, drug resistance, G6PD 
deficiency, and low-parasitemia infections, but they are too expensive and technically difficult to 
be used at the point of care. This dissertation focuses on understanding the issues facing current 
diagnostic and investigates strategies to improve them. Chapters II and III focus on protein-based 
diagnostics, while Chapters IV and V move on to DNA-based diagnostics as an ultimately more 
useful and versatile diagnostic format. Chapter II discusses the optimization of a transition 
metal-based detection strategy for the protein biomarker PfHRP2 as an alternative to typical 
antibody-based diagnostics. Chapter III investigates the structural changes in PfHRP2 when the 
protein binds to heme, and explores the effects of these changes on antibody binding to the 
protein. These two chapters also discuss the issues associated with protein-based malaria 
diagnostics.  
Chapter IV moves forward into DNA-based malaria diagnostics, as they can provide a 
wider variety of information necessary for effective malaria control. This chapter describes a 
DNA extraction method that was developed in order to simplify sample processing for DNA 
diagnostics. The method was then incorporated into an automated extraction device to further 
simplify the process, and then combined with in-line PCR to allow for sample-to-answer DNA 
diagnostics with minimal user interaction. Finally, Chapter V describes the development of a 
DNA-based RDT and an enzyme-free pre-amplification strategy which eliminates the need to 
run PCR before the RDT. Taken as a whole, this work follows the research goals of the malaria 
community, which was previously focused on further understanding and improving current 
protein diagnostics. In the past few years, however, the community realized that DNA 
diagnostics have the potential to be more robust and provide more detailed information than 
protein, but DNA diagnostics are currently hindered by their reliance on expensive, technically 
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challenging PCR. While this work cannot completely fill the need for new, easily accessible 
malaria diagnostics, it can provide new tools and understanding to work towards the goal of 
malaria elimination. 
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CHAPTER II 
 
 
 
ON-PARTICLE DETECTION OF PLASMODIUM FALCIPARUM HISTIDINE-RICH 
PROTEIN 2 BY A “SWITCH-ON” IRIDIUM(III) PROBE1 
 
 
 
Introduction 
Detection of molecular biomarkers via colorimetric and fluorescent signaling is important 
for a wide range of biochemical applications from molecular tracking to diagnostics.2,3 Low-
molecular weight organic dyes are the most commonly used reagents in biological studies.4,5 
Unfortunately, these organic fluorophores are subject to photobleaching, typically show small 
stokes shifts and have broad, often overlapping, emission spectra. Enzymatic labeling of 
biomolecular scaffolds is widely used in immunoassays and western blots for quantification of a 
specific antigen.6 Despite production of an amplifying, highly detectable colorimetric signal, the 
enzymes and their substrates can be sensitive to light, environmental conditions and non-specific 
protein interferents. Further, many cofactors or co-reagents, such as hydrogen peroxide, used in 
these reactions do not have long shelf lives. An alternative has been the use of inorganic 
fluorescent probes, including quantum dots and metal-based emissive complexes. 
Quantum dots are semiconducting nanocrystals that emit visible light based on their 
composition and size.  Electron-hole pairs, known as excitons, formed during excitation 
recombine and releases photons in narrow, long-lived symmetric energy bands.7 Tuning the size 
and surface functionalization of quantum dots allows them to be used for multiplexed detection 
of biomolecules.  However, surface defects trap excitons and prevent light emission, which leads 
to reduced quantum yield as well as the “blinking” phenomena common to quantum dot 
methods.  Originally developed as nuclear magnetic resonance (NMR) and magnetic resonance 
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imaging (MRI) reagents, metal lanthanide complexes have recently been used for immunoassays 
and cellular imaging. These probes are marked by long lifetimes and large Stokes shifts, but the 
intricate synthetic pathways necessary for probe stability limit their use in biological settings.8,9 
An alternative class of signaling probes is based on emissive transition-metal complexes.  
The light emitting properties of cyclometalated Ir(III) have been studied in various applications, 
including organic light emitting diodes (OLEDs),10–12 oxygen sensing,13 catalysis,14 and cell 
staining.15 Cyclometalated Ir (III) complexes are characterized by thermal and chemical stability, 
large Stokes shifts, long lifetimes, high quantum efficiency and photostability.16,17 Recently, Ma 
and coworkers demonstrated that cyclometalated Ir(III) complexes of the form [Ir(C^N)2(solv)2]+ 
selectively bind histidine and histidine containing peptides.15,18 When irradiated with long wave 
UV light, these complexes are non-emissive in their solvento state. In the presence of histidine, 
the associated solvent molecules are displaced as the histidine binds the metal center. Due to this 
ligand substitution, metal ligand charge transfer (3MLCT) and ligand centered transfer (3LC) 
pathways are activated resulting in an intense blue-green phosphorescent signal is released as the 
triplet excited state electron relaxes to the ground state.11,16  
Enzyme linked immunosorbent assays (ELISAs) is a common method for the 
immunological detection of disease biomarkers. Regulation of histidine rich proteins have been 
associated with several diseases including liver cirrhosis, cancer and thrombic disorders.19 For 
malaria, Plasmodium falciparum Histidine Rich Protein 2 (PfHRP2) has long been validated as a 
major biomarker of malarial infection.  PfHRP2 is a 67 kDa protein comprised of 34% histidine, 
is secreted by the parasite into the blood of the host.20 The primary amino acid structure of this 
protein is marked by characteristic AHHAHHAAD motifs, which have been shown to bind free 
metal ions20 as well as heme complexes.21 Immunochromatographic rapid diagnostic tests 
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(RDTs) have become important diagnostic tools in low-resource settings. Unfortunately, RDT 
efficacy is often limited by sample condition and purity, target concentration, manufacturing 
quality control, environmental conditions, and antibody failures.22 
Metal-based phosphorescent probes are excellent candidates for the detection of this 
protein due to their selective, stabile and efficient emission properties. In this chapter, we 
elucidate the optimal reaction conditions (e.g. buffer, temperature, pH) as well as assess the 
detection limits of [Ir(ppy)2(H2O)2]+ (Ir1) toward BNT-II, a branched peptide mimic of 
PfHRP2.23 Using the optimized assay conditions, we demonstrate low nanomolar limits of 
detection when the recombinant HRP2 (rcHRP2) is bound to the surface of 50  µM magnetic 
Ni(II)NTA agarose particles in a solution-based ELISA format. This assay can be performed in 
less than 2 hours using simple, antibody-free reagents, as compared to traditional ELISAs that 
take 4-5 hours and require sensitive biological reagents. 
 
Materials and Methods 
Materials and Reagents 
 Dichlorotetrakis(2-(2-pyridinyl)phenyl)diiridium(III) (diIr1), silver 
trifluoromethanesulfonate (AgOTf), L-alanine (Ala), L-Histidine (His), L-Cystine (Cys), L-
Tryptophan (Try), L-Valine (Val), L-Lysine (Lys), L-Isoleucine (Ile), L-Aspartic Acid (Asp), L-
Phenylalanine (Phe), L-serine (Ser), bovine serum albumin (BSA), phosphate buffered saline 
(PBS) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were purchased from 
Sigma-Aldrich.  BNT-II was synthesized in the laboratory according to previously published 
methods.23 Recombinant HRP2 (rcHRP2) was purchased from Immunology Consultants 
Laboratory Inc.  Costar black and white polypropylene 96-well plates were purchased from 
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Fisher Scientific. 50 µM Ni(II)NTA magnetic agarose particles were purchased from Qiagen. All 
other reagents or buffers were purchased from either Sigma-Aldrich or Fisher Scientific. 
 
Instrumentation 
 1H NMR spectra of Ir1 in CDCl3 were recorded using a Bruker AV-400 instrument at 400 
MHz.  Electrospray ionization mass spectra (ESI-MS) of Ir1 in MeOH were measured with a 
Finnigan LCQ ion trap LC-MS with ESI ionization. UV-visible spectra were recorded with an 
Agilent 8453 UV-Visible spectrophotometer. Phosphorescence measurements were recorded 
using a BioTek Synergy H4 microplate reader. Cyclic voltammetry (CV) measurements of 200 
µM Ir1 in degassed acetonitrile were recorded on a CHI1030 potentiostat (5 V/s scan rate). 
Glassy carbon was used as the working electrode and platinum wire as the counter electrode.  
Ag/AgCl was used as the reference electrode with ferrocene as the internal standard. 
 
Synthesis of Iridium(III) Complex Ir1 
The complex Ir(ppy)2(H2O)2+, Ir1, was synthesized using a previously published 
method.24 50 μM diIr1 was dissolved in 5mL of methylene chloride before the addition of 100 
μM solution of AgOTf in methanol.  The slurry was stirred for 1hr at room temperature. 
Afterwards, the slurry was filtered through Celite, and the filtrate was evaporated until 1-2 mL of 
filtrate remained.  The remaining filtrate was lyophilized overnight yielding a bright yellow 
powder. 1H NMR (400 MHz, CDCl3, d=ppm): 6.1047(H3A, doublet) 6.7061(H4A, triplet) 
6.8631(H5A, triplet) 7.3657(H5B, doublet) 7.5236(H6A, doublet) 7.8926(H3B, H4B, 
overlapping resonances) 9.015(H6B, doublet); CV: Ep (1.64V vs NHE) Eh (1.569V vs NHE) 
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Activity of Ir1 against Amino Acids and Biomolecules 
Interactions between Ir1 and various amino acids, peptides and proteins were elucidated 
by observing changes in the phosphorescent emission upon reacting 50 μM Ir1 with these 
molecules.  All reactions and titrations were performed in black 96-well plates at a total volume 
of 100 μL.  2.5 μL of 2 mM Ir1 in methanol was added to 100 μL solutions of a given 
biomolecule to bring the final concentration of Ir1 in each well to 50 µM. 
 
Amino Acid Selectivity of Ir1 
 50 μM of Ir1 was incubated for 10 minutes with individual 100 μL solutions of the 
following amino acids: Ala, Asp, Cys, His, Ile, Lys, Ser, Try, and Val (n=3 for each amino acid).  
After the 10-minute incubation period, emission spectra of all amino acids were taken using the 
BioTek Synergy H4 plate reader (365ex/400-700em). 
 
Optimization of In-Solution Assay Parameters 
 In order to optimize the reaction conditions for the assay, 50 μM Ir1 was incubated with 
L-Histidine under various conditions (e.g. buffer type, pH, temperature, incubation time).  
Spectral scans (365ex/400-700em) and endpoint measurements (365ex/ 510em) were taken using 
the BioTek Synergy H4 plate reader. 
 
In-Solution Limit of Detection of 6-His, BNT-II and rcHRP2 
 50 μM of Ir1 was titrated with varying nanomolar concentrations of BNT-II and rcHRPII 
in order to determine the limit of detection for each biomolecule.  After a 10-minute incubation 
period, spectral scans (365ex/400-700em) and endpoint measurements (365ex/ 510em) were 
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taken using the BioTek Synergy H4 plate reader.  Limit of detection was defined as the value of 
x when y = 3σblank. 
 
On-Particle Limit of Detection of BNT-II and rcHRP2 
1 µM BNT-II and rcHRPII were serially diluted by half in HEPES Buffered Saline with 
Tween (HBST; 100 mM HEPES, 137 mM NaCl, pH 7.4, 0.25% Tween-20) and incubated with 
10 µL of 50 µM Ni(II)NTA magnetic agarose particles for 15 minutes in a white 96 well plate 
(n=6; 100 µL for each concentration of BNT-II and rcHRPII).  After the incubation period, the 
particles were washed 3 times with 250 µL of HBST using a 96 well plate magnetic rack.  After 
washing, the particles were resuspended in 100 µL HBST and 2.5 µL of 2 mM Ir1 was added to 
each well.  The biomarker bound particles were incubated with Ir1 for 60 minutes before 
endpoint measurements (365ex/ 510em) were taken using the BioTek Synergy H4 plate reader.  
Limit of detection was defined as the value of x when y = 3σblank.  The statistical significance of 
the limit of detection of the on-bead assay to the in-solution assay was determined by an 
unpaired t-test using the Prism 5.0 graphing software. 
 
Results and Discussion 
Physical and Spectroscopic Characteristics of Ir1 
Synthesis and characterization of cyclometalated Ir(III) complexes have been studied for 
several years for a wide range of applications.  Following the synthetic route outlined in Figure 
2.1,24 a bright yellow powder was obtained and characterized to be [Ir(ppy)2(H2O)2]+ (Ir1).  The 
solvento-complex was synthesized by first splitting the chloride bridge in the [Ir(ppy)2(Cl)]2  
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dimer by precipitation of the chloride in the form of an insoluble silver salt. Water molecules 
associate to the metal center to form a stable cationic complex.  1H NMR,24 ESI and CV14 
confirmed formation of Ir1 (Appendix A, SI Figure 2.1 to 2.3). High energy absorption bands 
were found in 200-300 nm region of the UV-Visible spectrum of 200 µM Ir1 in methanol, while 
weaker bands in the 350-500 nm region were assigned to metal-ligand charge transfer (1MLCT 
and 3MLCT) and intraligand transitions (π-π*) (Appendix A, SI Figure 2.4).18  In solution, Ir1 
exhibited no emissive properties upon excitation at 365 nm. 
 
Figure 2.2. Interaction of 200 µM of various amino acids (Cys, Ser, Asp, Glu, Phe, Lys, Arg, 
Tyr, Trp, and His) with 50 µM Ir1 in 100 mM PBS. Signal in relative fluorescence units (RFU) 
from all amino acids besides histidine (dashed black trace) was negligible. 
Figure 2.1. Chloride bridge splitting reaction of dichlorotetrakis(2-(2-
pyridinyl)phenyl)diiridium(III) (diIr1) to create the aquo complex Ir(ppy)2(H2O)2+ (Ir1). The 
reaction is driven by precipitation of AgCl as an insoluble salt. On the addition of a histidine-
containing peptide, the water molecules are displaced from the metal as the imidazole side chain 
binds. 
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Optimization of Ir1 Signal with L-Histidine 
 The specificity of Ir1 toward L-Histidine (L-His) was investigated to confirm complex 
specificity. After reacting Ir1 with each of the 20 amino acids, only L-His coordinatation elicited 
a phosphorescent response at 510 nm (Figure 2.2), consistent with previously published results.18 
The water molecules are displaced from the Ir(III) metal center by ligand substitution with L-His 
to create an emissive bioconjugate.  The strong sdonor nature of the C^N ligands pushes electron 
density to the metal center. Upon binding histidine and excitation with 365nm UV light, the 
singlet excited state (1MLCT/1LC) of the Ir(III) bioconjugate undergoes intersystem crossing to 
the triplet excited state (3MLCT) and “switches on” the phosphorescent signal at 510 nm.  
 
 
Figure 2.3. A) Relative fluorescence signal intensity (RFU) of 50 µM Ir1 with varying 
concentrations of L-His in 100 mM PBS and 100 mM HEPES buffers, B) Effect of adding 137 
mM NaCl to 100 mM HEPES buffer on the signal intensity of 50 µM Ir1 with varying L-His. 
 
 It is well known that the solution environment can change the photophysical properties of 
an emitting compound.25 Additionally, coordinating buffers, such as phosphate buffer, can 
complex with metal ions, leading to insoluble precipitates.  Although previously published 
methods used similar iridium probes in phosphate buffer, it was noted that Ir1, if stored in 
phosphate buffered saline (PBS), gradually precipitated as a yellow solid. The bidentate 
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phosphate anion was likely displacing the water molecules and deactivating the Ir(III) complex 
via the formation of an insoluble salt. By switching to HEPES, a non-coordinating zwitterionic 
buffer, the signal response of Ir1 to L-His increased 3-fold (Figure 2.3A). 137 mM NaCl was 
added to the HEPES buffer (HBS) to more closely mimic the salt concentration found in PBS 
solutions.  This addition of salt increased the sensitivity of Ir1 toward L-His by a factor of four 
(Figure 2.3B). 
 To further explore this shift toward signal saturation of Ir1/L-His conjugate in the 
presence of salt, the reaction kinetics of 10 µM L-His with Ir1 in phosphate buffer (PB), PBS, 
HEPES, and HBS was monitored at 510 nm over the course of 2 hours (Figure 2.4).  Both PBS 
and HBS showed a rapid increase in signal during the first 20 minutes of the reaction; however, 
signal began to stabilize after 30 minutes.  A similar trend was seen in PB, but the saturated 
signal was approximately half of that from PBS.  The reaction coordinate in HEPES deviated 
from the previous buffer systems in that the signal steadily increased over the course of 100 
minutes.  The effect of the coordinating phosphate anion on the loss of signal is apparent in the 
reaction of L-His with Ir1 in PB alone versus HEPES. 
 
Figure 2.4. Reaction kinetics of 10 µM L-His with 50 µM Ir1 with various buffers. 
 23 
 The presence of NaCl in both phosphate and HEPES buffers appeared to increase target 
complexation to Ir1 when compared with their salt deficient counterparts.  This is likely due to a 
kinetic salt effect that the addition of NaCl to the buffer has the on the interaction between the 
probe and histidine.26 In neutral buffer conditions, both Ir1 and L-Histidine are positively 
charged and thus are slightly repelled from each other in solution.  This is evidenced in the slow 
generation of signal in PB and HEPES buffer systems.  The addition of negatively charged 
chloride ions forms a charge screen around the reactants as governed by the Debye-Huckel 
theory,27 which in turn lowers the energy of the reactants and enhances the interaction between 
the two species as seen by the rapid increase in signal in the first 10 minutes in PBS and HBS. 
Given these results, the amino acid specificity of Ir1 was then reanalyzed in HBS to ensure 
specificity to L-His alone was maintained (Appendix A, SI Figure 2.5).  
 
 
Figure 2.5. Effect of A) varying pH and B) temperature on the relative fluorescence intensity 
(RFU) of L-His with 50 µM Ir1 in 100 mM HBS. 
 
 The effect of pH and temperature on signal generation was determined (Figure 2.5A).  
Below pH 6, very little signal was observed.  However, above pH 6, signal from the Ir1/L-His 
conjugate reached saturation around 50 µM L-His. This correlation between intensity of signal 
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and pH is related to the pKa of histidine. In order for histidine to bind to the Ir(III) metal center, 
the nitrogen on the imidazole ring must be deprotonated. It was observed that signal intensity 
correlated directly to this “working” concentration of deprotonated histidine (Appendix A, SI 
Figure 2.6), calculated from the Henderson-Hasselbach equation.  Below pH 6, there were fewer 
histidine molecules available for binding, which in turn reduced signal.  Therefore, pH 7.4 was 
selected as the operational pH for HBS in the assay. When creating a diagnostic probe for 
possible use in a wide range of climates and conditions, operational temperature must be taken 
into account to ensure the diagnostic result will be consistent and independent of the 
environment. The signal response at room temperature (RT) and 80°C was not statistically 
different over a range of histidine concentrations (p < 0.05), but at 4°C the signal response 
decreased two-fold (Figure 2.5B). At lower temperatures, the complexation of L-histidine is 
likely slower than at temperatures above 25°C, resulting in less signal. 
 The optimized assay conditions for use of the Ir1 probe was standardized to be 100mM 
HEPES buffer, pH 7.4 with 137 mM NaCl at temperatures at or above room temperature. At the 
assay conditions, the quantum yield of the Ir1/L-His conjugate agreed with previously published 
data (Appendix A, SI Figure 2.7).18 In a field where antibody-coupled technologies are the 
current “gold-standard” for biomarker detection, the robust nature of Ir1 offers a number of 
advantages as a diagnostic in probe low-resource settings. 
 
Development of Optimized Ir1 Assay with a PfHRP2 Mimic 
With optimized reaction conditions, an assay was designed for the detection of the 
malaria biomarker HRPII. Optimization of the assay with L-Histidine as opposed to the whole 
protein allowed for fine-tuning of the basic buffer components prior to introducing the probe to a  
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Figure 2.6. Structure of the PfHRP2 mimic, BNT-II. 
 
more complex spatial environment. Initial experiments utilized BNT-II, a branched peptide 
synthesized to mimic the primary repeating AHH/AHHAAD units characteristic of PfHRPII,23 as 
the target (Figure 2.6).  Comparing absolute signal generated on a molar basis, BNT-II yielded 
higher signal response than L-His upon incubation with Ir1 (Figure 2.7A). It was also noted that 
upon comparing signal response versus concentration of total histidine, BNT-II, with 32 histidine 
residues per molecule, the concentration of histidine necessary for signal saturation was reduced 
16-fold from L-His (Figure 2.7B). Beyond 100 µM L-His, the signal leveled off as Ir1 became 
the limiting reagent.  If all of the imidazole side chains in BNT-II were available to bind Ir1, the 
two curves would overlap.  Since we do not see this trend, we know stoichiometric signal 
generation is not achieved in the BNT-II system. This could be the result of either non-
stoichiometric binding of Ir1 to BNT-II or quenching of the bound probes. While we may 
assume Ir1 would preferentially bind adjacent histidine residues in the AHH motif, the probe 
could bind across the alanine in the HAH region, effectively reducing the signal by a factor of 2 
(Appendix A, SI Figure 2.8). Additionally, steric bulk around the lysine linker core of the 
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peptide may prevent iridium from assuming the correct coordination geometry for binding.23 
Aside from non-stoichiometric binding of the probe to the target, photophysical quenching could 
be occurring in the system.  Because of the structure of BNT-II, any bound Ir(III) probes would 
be in close proximity in chemical space and triplet-triplet annihilation could occur.28 This 
annihilation effect would cancel two excited triplet states in the Ir(III) bioconjugate and relax the 
energy back to the ground state. While quantum yield of BNT-II with Ir1 was determined to be 
8.3% (Appendix A, SI Figure 2.7) further analysis of this possible quenching effect is outside of 
the scope of this chapter. 
 Depending on the severity of infection, clinically relevant limits of detection of PfHRP2 
can fall in the low picomolar to low micromolar regime.29 Using the optimized assay conditions, 
detection of the clinical biomarker recombinant HRP2 (rcHRP2) was assessed with the probe 
(Figure 2.8). When concentration of the protein was converted to concentration of total histidine, 
the titration curve was very similar to that of BNT-II, indicating that a similar loading/quenching 
effect is likely occurring in the rcHRP2/Ir1 system (Appendix A, SI Figure 2.9). Regardless of 
 
 Figure 2.7.  A) Relative fluorescence intensity (RFU) of solution concentrations of L-His and 
BNT-II and B) Correlation between RFU and total histidine concentration in L-His and BNT-II. 
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these effects, the limit of detection in solution was determined to be 54.8nM and 12.8nM for 
BNT-II and rcHRPII, respectively. 
 
Figure 2.8. Titration of nanomolar concentrations of BNT-II and rcHRP2 with 50 µM Ir1 in 
HBS. 
 
Ir1 Assay for the On-Bead Detection of PfHRP2 
 With the advent of microparticle-based diagnostic tools, the ability to detect a target 
biomolecule on the surface of the particle becomes increasingly advantageous. Current methods 
for the detection of disease protein biomarkers rely heavily on antibody-based techniques such as 
enzyme linked immunosorbent assays (ELISAs) and gold nanoparticle conjugates.30 ELISAs can 
achieve low picomolar limits of detection, but the entire assay takes 4-5 hours, relies on 
temperature and time-sensitive reagents, and requires specialized equipment and trained 
technicians. Due to the interesting optical and aggregation properties of colloidal gold 
nanoparticles (AuNPs), assays have recently emerged utilizing these colloids for protein 
biomarker detection.31 Antibodies or metal-affinity ligands have been conjugated to the surface 
of the AuNPs for the capture and detection of proteins.32 These conjugates are often used in the 
lateral flow rapid diagnostic tests manufactured for the detection of the malaria biomarker 
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PfHRP2.  Despite maintaining a low-resource design, the thermal instability of the antibody-
AuNP conjugate impedes the accuracy of the assay.33 
 
 
Figure 2.9. A) Comparison of a standard sandwich ELISA format and the Ir1 on-particle assay. 
B) Titration of nanomolar concentrations of rcHRP2 in the on-particle Ir1 assay. 
 
In previous studies, 50 µM Ni(II)NTA magnetic agarose particles bind PfHRP2 through 
the imidazole side chains and facilitate the purification of the biomarker away from 
contaminating blood proteins and cellular debris.29 Many histidine residues would still be 
available for coordination to the iridium probe when the protein is bound to the surface of the 
particle.  By labeling the bound histidine rich biomarker, we are effectively creating a solution-
based sandwich ELISA assay that is complete in 1.5 hours without needing several hours of 
processing time and environmentally sensitive antibody reagents (Figure 2.9A). The use of 
magnetic particles to immobilize the target biomarker for processing is the key component for 
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the reduction of assay time.  In a normal ELISA format, each reagent is immobilized on the well 
plate in 1-2 hour steps, and the plate must be washed extensively in between these steps to 
remove any unbound reagents. Our modified ELISA assay has fewer overall steps than a normal 
ELISA format however; magnetic particles can be intermixed with the sample for more efficient 
binding, and the particles can be pulled down to the bottom of the reaction chamber for fast 
washing. 
 Qualitatively, we were able to visualize the iridium on the surface of the particle under 
long-wave UV light (Appendix A, SI Figure 2.10). Optimal protein binding times increased 
from 10 minutes in the case of free protein in solution to 45 minutes for bead bound target 
(Appendix A, SI Figure 2.11). This is likely due to decreasing degrees of freedom of HRP2 to 
react with Ir1 upon binding to the surface of the particle.  Using the optimized assay conditions, 
the limit of detection for rcHRP2 on-particle was 14.5 nM (0.972 µg/mL), with no signal 
generated from the blank (Figure 2.9B).  The linear range of the assay spans three orders of 
magnitude in the nanomolar regime.  Beyond this range, the signal becomes saturated, likely due 
to quenching effects and/or the probe being the limiting reagent at increasing concentrations of 
target. The limit of detection for rcHRP2 in-solution and on-bead were statistically the same 
based on an unpaired t-test (p = 0.731), thus validating both the magnetic particle’s binding 
capacity as well as the probes ability to detect the biomarker when immobilized on a surface. 
 
Conclusion 
This chapter describes the utility of a cyclometallated Ir(III) probe for the selective 
labeling and detection of the malarial biomarker PfHRP2 on the surface of a magnetic particle.  
By first optimizing several assay parameters, the Ir1 probe was used for the detection of low 
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nanomolar amounts of rcHRP2 bound to the surface of the particle. This type of on-particle assay 
mimics that of a traditional ELISA design performed in a 96-well plate, but the assay is complete 
in under two hours, due to the use of magnetic particles for biomarker immobilization, 
processing and detection.  While the limit of detection fell within the symptomatic range 
required for the clinical diagnosis of malaria, detection of increasingly low picomolar levels of 
PfHRP2 has become necessary for the identification of asymptomatic patients, who serve as 
transmission reservoirs for the disease.  This is seen in comparing the curve of the presented on-
bead assay to a traditional ELISA for PfHRP2 (Appendix A, SI Figure 2.12).  In addition, Ir1 is 
specific for histidine but not for PfHRP2.  The presence of additional histidine containing 
proteins, such as human serum albumin or histidine rich glycoprotein, could give false positives 
for the proposed assay design. This was evidenced by background signal generated from the 
surface of particles that were incubated with unspiked diluted plasma that was 6-fold higher 
intensity than that of rcHRP2 (data not shown). Selective isolation of the target protein away 
from contaminating proteins, using our recently published rapid extraction cassette,29 would 
greatly enhance this probe’s utility in a field diagnosis setting.  Additionally, several strategies 
can be explored to achieve lower detection limits and specificity, comparable to that of a 
traditional ELISA format, namely the creation of a branched histidine containing peptide that can 
be conjugated to molecular recognition elements (MREs), such as antibodies or aptamers. By 
coupling this peptide to an HRP2-specific MREs, we can simultaneously target HRP2 and 
enhance the signal via the branched histidine motifs.  These modifications to the probe would 
push the magnetic particle based Ir(III) assay toward higher signal output for ease of biomarker 
detection by the end user. 
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CHAPTER III 
 
 
 
STRUCTURAL CHARACTERIZATION OF RECOMBINANT PfHRP2 BINDING TO HEME 
AND EFFECTS ON RAPID DIAGNOSTIC TEST PERFORMANCE 
 
 
 
Introduction 
 
 Early diagnosis of malaria is a key element in elimination strategies because individuals 
with low parasite loads can still serve as transmission reservoirs.1–4 However, the most common 
field diagnostic for malaria, rapid diagnostic tests, often show variable performance at low 
parasite densities.5,6 Rapid diagnostic tests (RDTs) are often used in widespread malaria 
screening efforts to quickly and easily detect the malaria biomarker Plasmodium falciparum 
histidine-rich protein 2 (PfHRP2) in a small drop of blood. However, there are many external 
factors that can adversely affect the performance of these tests in field diagnostic settings, such 
as heat degradation and humidity.6 For several years, these tests suffered from poor 
manufacturing standards, and certain brands vastly outperformed other brands.6 In order to 
inform purchasing decisions and enforce standards, the World Health Organization began a 
biannual review process for malaria RDTs which has improved the overall quality of tests 
available.7 While the tests themselves have become more reliable, parasite evolution has affected 
their utility as well. PfHRP2 protein sequence variations8,9 and even gene deletion10,11 have been 
reported in areas of Southeast Asia and South America, which means that even the best PfHRP2 
test will not be an effective malaria diagnostic in these areas. Current diagnostic developers are 
constantly trying to stay one step ahead of the parasite by investigating new diagnostics and 
working to improve the PfHRP2 diagnostics that are already in use. 
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Assay developers use recombinant protein as a standard for assay validation. 
Recombinant proteins are produced using bacteria (typically E. coli) that have been genetically 
modified to produce the protein sequence of interest. After expression, the protein is purified 
from the bacteria and characterized, and it can be used in the same way as native protein. 
Recombinant proteins are also used in antibody production because the sequence and purity can 
be controlled more so than a native protein. However, because the protein sequence is not in its 
native environment, a recombinant protein often does not possess the same folding or three-
dimensional structures as the native protein. This can be a problem when the correct secondary 
and tertiary structure of the protein is essential for assay function, as in antibody-based assays 
such as RDTs or enzyme-linked immunosorbent assays (ELISAs).  
Past studies have indicated that PfHRP2 may play a role in the parasite’s heme 
detoxification process by binding free heme and promoting its crystallization into hemozoin.12,13 
During the parasite lifecycle, PfHRP2 is excreted into circulating blood as the parasitized red 
blood cells burst, allowing the parasites to infect new red blood cells.14 Circulating blood 
contains heme mostly in its protein-bound hemoglobin form, but data from our lab indicates that 
parasitized blood also contains ~10 µM free heme. These two observations together indicate that 
a blood sample used for PfHRP2 detection will have some proportion of its PfHRP2 bound to 
free heme. We hypothesize that heme-bound PfHRP2 adopts a different conformation from free 
protein, and that this conformational change may affect protein binding to antibodies on an RDT. 
Previous studies have shown that binding heme alters the structure of rcPfHRP2, but the effects 
of these changes have not been investigated.15 This is especially a concern since native protein 
will be exposed to heme in blood as described above, but purified recombinant protein used for 
industrial antibody production will not be exposed to heme.  
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This chapter is focused on investigating the structure of PfHRP2 and its relationship to 
the effectiveness of current RDTs. Specifically, we investigate the conformational changes of 
recombinant (rc) PfHRP2 in the presence of heme using circular dichroism (CD), and the effects 
of these structural changes on antibody-based PfHRP2 detection using ELISA and RDT formats. 
Understanding how the structure of rcPfHRP2 changes with its environment can help us design 
more sensitive, effective diagnostic tests for malaria. 
 
Materials and Methods 
Materials and reagents 
 Various recombinant forms of PfHRP2 (ITG and FCQ79) were obtained from PATH. 
CTK PfHRP2 was purchased from CTK Biotech (Cat # A3000). Hemin chloride was purchased 
from MP Biomedicals, LLC (Cat # 198820). Zn(II)PPIX was purchased from Frontier Scientific 
(Cat # Zn625-9). Fisherbrand clear 96-well polystyrene plates were purchased from Fisher 
Scientific (Cat # 12565501). The 2mm microcell CD cuvette was purchased from Aviv 
Biomedical (Cat # 1301-101000-2) and used with a microcell spacer also purchased from Aviv 
Biomedical (Cat # 0021-100190-1). Spectra-Por Micro Float-A-Lyzer 100 – 200 µL 8 – 10 kDa 
MWCO dialysis devices were purchased from Fisher Scientific (Cat # 08-607-075). Amicon 
Ultra 0.5 mL 3 kDa MWCO centrifugal filters were purchased from Millipore (Cat # 
UFC500324). Antibodies for the PfHRP2 ELISA were purchased from Abcam Inc. (Cat # 
ab9206 and ab30384). Paracheck Pf RDTs were acquired from Orchid Biomedical Systems (Cat 
# 30301025). SD Bioline Malaria Ag Pf RDTs were purchased from Standard Diagnostics Inc. 
(Cat # 05FK50). ICT Pf RDTs were purchased from IDT Diagnostics (Cat # ML01). All other 
reagents and buffers were purchased from either Sigma-Aldrich or Fisher Scientific. 
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Instrumentation 
 Absorbance measurements were taken using a Synergy H4 microplate reader and a 
NanoDrop ND-1000 spectrophotometer. Circular dichroism measurements were recorded using 
an Aviv Model 215 CD Spectrometer. RDT signal measurements were taken using a Qiagen 
ESEQuant Lateral Flow Reader.  
 
Absorbance Titrations 
 ITG rcPfHRP2 was buffer exchanged to 20 mM potassium phosphate buffer, pH 7, (PB) 
using Zeba 7K MWCO Spin Desalting Columns. Absorbance spectra of blank PB and 5 µM ITG 
rcPfHRP2 were taken from 250 – 700 nm in a UV-transparent 96-well plate. The rcPfHRP2 
wells were brought to 15 µM heme by adding 2.86 µL of 1mM hemin in 100 mM NaOH to the 
samples, which were then mixed and incubated at room temperature for 15 minutes before 
another absorbance spectrum was recorded. Hemin additions, incubation, and absorbance 
measurements were continued until 18 molar equivalents of hemin had been added to the protein 
samples. For comparison, absorbance spectra were recorded for the same concentrations of 
hemin in PB without protein present. 
 
Circular Dichroism Spectroscopy of Various rcPfHRP2 Proteoforms  
 ITG rcPfHRP2 was buffer exchanged to 20 mM potassium phosphate buffer, pH 7, (PB) 
using Zeba 7K MWCO Spin Desalting Columns. Protein concentration (typically 3 – 5 µM) was 
determined by measuring A220 using a NanoDrop ND-1000 spectrophotometer. Circular 
dichroism spectra of samples and blanks were recorded from 185 – 260 nm with wavelength step 
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0.5 nm and 3 scans per sample using a 2 mm pathlength microcell in an Aviv Model 215 CD 
Spectrometer. 1 mM hemin in 100 mM NaOH was added to each protein sample in 3 molar 
equivalent increments. After each addition, the solution was pipetted to mix and allowed to 
incubate at room temperature for 15 minutes before another CD scan was run. Data was 
averaged, smoothed, and background subtracted using Aviv 215 CD software. These 
experiments were repeated using additions of 1 mM Zn(II)PPIX in 100 mM NaOH in place of 
hemin additions, and using additions of 100 mM NaOH alone to control for volume effects. 
 After 15 molar equivalents of heme was added to certain samples, they were subjected to 
dialysis or centrifugal filtration to determine if observed structural changes were reversible. For 
dialysis, Micro Float-A-Lyzer 8 – 10 MWCO dialysis devices were used according to the 
manufacturer’s instructions. Briefly, the membrane was first soaked in 10% ethanol for 10 
minutes to remove glycerin before being flushed thoroughly with DI water. Next, after all air 
was removed from the device, 100 µL of heme-bound protein sample was added to the device. 
The device was placed in 100 mL of PB, which was stirred for 22 hours with buffer changes at 2 
hours, 6 hours, and 10 hours. Sample was retrieved from the device and analyzed via CD as 
above. For centrifugal filtration, Amicon Ultra 3K MWCO centrifugal filters were used 
according to the manufacturer’s instructions. Briefly, 75 µL of heme-bound protein sample was 
added to the device along with 400 µL PB. The filter was centrifuged for 30 minutes at 14,000g 
and the filtrate was discarded. 400 µL PB was added to the filter and centrifuged twice more. 
Finally, the filter device was flipped over into a new collection tube and centrifuged for 2 
minutes at 1,000g to collect the sample. The sample volume was 35 µL due to the concentration 
effect of the filter, so 40 µL PB was added to bring the sample to an adequate volume for CD 
analysis, and the sample was analyzed via CD as above. 
 39 
 Temperature experiments were conducted via CD in two ways. First, a full spectrum was 
taken as above for samples of rcPfHRP2 with and without heme, both at room temperature and at 
85°C. Then, a temperature step experiment was run by subjecting rcPfHRP2 samples to gradual, 
controlled temperature change, and recording CD data at 222 nm every 1°C. 
 
Rapid Diagnostic Test Studies 
 The effect of heme on the detection of varying amounts of rcPfHRP2 was tested using 3 
RDT brands. Various concentrations of ITG rcPfHRP2 in PBS were prepared, both with and 
without 10.64 molar equivalents of heme in solution. The samples that included heme were 
allowed to incubate for 15 minutes at room temperature before testing. All samples were run in 
triplicate on 3 different RDT brands (Paracheck, SD Bioline, and ICT Pf) according to 
manufacturer instructions. RDT signal was measured using a Qiagen ESEQuant LFA Reader 
with channel and type set to E1/D2 and reflective, respectively. 
 The effect of heme concentration on the detection of a single rcPfHRP2 concentration 
was also tested using SD Bioline RDTs. Several samples of 28.2 nM ITG rcPfHRP2 were 
prepared with varying molar equivalents of heme added and allowed to incubate for 15 minutes 
at room temperature. All samples were run in triplicate on SD Bioline RDTs according to the 
manufacturer’s instructions. RDT signal was measured using a Qiagen ESEQuant LFA Reader 
with channel and type set to E1/D2 and reflective, respectively. 
 
ELISA Studies 
 An in-house ELISA was used to quantify rcPfHRP2 binding to antibodies.16 A 100 µL 
solution of 1 µg/mL IgM anti-HRP2 (Abcam ab9206) in 1X PBS was added to each well of a 
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Immulon 2 HB 96-well plate, which was then sealed with Parafilm and allowed to incubate for 1 
hour on an orbital shaker. After incubation, the plate was washed 3 times with 300 µL of 1X 
PBS containing 0.1% Tween-20 (PBST). Next, 300 µL of a solution of PBST with 5% BSA (by 
weight) was added to each well and incubated for 2 hours. The plate was then washed three times 
with PBST before adding 100 µL per well of the standard curve, controls and samples. The 
standard curve consisted of ITG rcPfHRP2 serially diluted from 5 pM to 0.078 pM in PBST with 
0.1% BSA. Samples consisted of 0.5 pM, 1 pM, or 3 pM ITG rcPfHRP2 in PBST with 0.1% 
BSA that had been incubated with various molar equivalents of heme for 15 mintues prior to 
ELISA analysis. The standards and samples were incubated for 2 hours, after which the plate 
was washed four times with PBST. Next, a 100 µL solution of 0.5 µg/mL IgG anti-HRP2 with 
HRP (Abcam ab30384) in PBST containing 0.5% BSA was added to each well and incubated for 
1 hour while protected from light. The plate was then washed five times prior to development. 
100µL of TMB One solution was added to each well and developed for 10 minutes in low light. 
The reaction was quenched with 100 µL of 2 M H2SO4. The absorbance at 450 nm was measured 
using a BioTek Synergy H4 microplate reader.  
 
Results and Discussion 
Effect of protein binding on heme absorbance 
 Absorbance spectra measurements were used to confirm that heme in solution will bind 
to rcPfHRP2. When heme absorbance is measured in phosphate buffer with no protein present, 
the spectrum shows a broad absorbance peak from 300 – 450 nm, centered at 370 nm (Figure 
3.1A). As expected, the signal intensity is related to the heme concentration in solution. When 
heme absorbance is read in the presence of 5 µM rcPfHRP2, a sharp Soret peak appears at 410 
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nm (Figure 3.1B). The appearance of this sharp red-shifted peak indicates that heme is 
coordinated to the protein.17 Furthermore, when the peak absorbance at 410 nm is plotted against 
heme concentration added to the protein, a linear trend is observed until 15 molar equivalents of 
heme have been added to the protein (Figure 3.1C). When 18 molar equivalents of heme are 
added to the protein, the Soret peak has the same intensity as the sample with 15 molar 
equivalents. This indicates that the protein can bind up to 15 heme molecules at pH 7 to reach 
saturation, consistent with previous literature.15  
 
 
Figure 3.1.  Absorbance spectra of varying concentrations of heme presented as molar 
equivalents relative to protein A) in PBS alone and B) incubated with 5 µM rcHRP2 in PBS. C) 
Linear trend of the Soret peak absorbance at 410 nm with increasing heme. 
 
Effect of heme binding on protein CD spectra 
 Circular dichroism was used to investigate the three-dimensional structure of several 
rcPfHRP2 variants at pH 7. These samples were then titrated with heme to observe structural 
changes resulting from heme binding to the protein. Tag-free variants of the protein such as ITG 
(Figure 3.2A) and FCQ79 (Figure 3.2B) produce spectra with a sharp, deep peak at 203 nm and 
a very shallow, wide shoulder centered around 222 nm. The peak at 203 nm is indicative of a 
strongly random-coil structure18,19, meaning that the protein is mostly globular without a 
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classically defined structure. As heme is added to the protein, however, the peak at 203 nm 
become less intense and shifts closer to 210 nm, while the broad band at 222 nm becomes more 
intense. The shape of the spectrum after 15 molar equivalents of heme have been added to the 
protein is strongly indicative of an a-helical structure18,19, especially for the FCQ79 variant where 
the peak intensity ratio is nearly 1:1. These results, combined with the absorbance data above, 
suggest that binding more heme molecules causes rcPfHRP2 to adopt a more rigid helical 
structure compared to its native, mostly unstructured state. 
 
 
Figure 3.2. Circular dichroism (CD) spectra of heme titrated into solutions of A) ITG rcPfHRP2 
and B) FCQ79 rcPfHRP2 in 20 mM phosphate buffer, pH 7. Each graph also shows a spectrum 
for the same sample after A) dialysis or B) centrifugal filtration. Heme is labeled as molar 
equivalents relative to protein concentration. 
 
To determine if the observed structural changes in untagged rcPfHRP2 were reversible, 
protein samples were filtered after heme addition and then re-analyzed via CD to see if the 
protein would return to its original state upon heme removal. Both centrifugal filtration and 
typical dialysis were used to filter samples in case one method was more effective than the other 
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(Figure 3.2). Each filtration method showed a peak shift from 210 nm to 203 – 204 nm, and a 
decrease in signal at the broad 222 nm band, indicating that the protein had indeed reverted to its 
mostly unstructured, random coil state. This shows that a simple sample preparation step could 
reduce the structural effect of heme binding in a purified protein. However, the overall CD signal 
decreased compared to the 15 heme traces and especially the 0 heme traces, which shows that 
both of these methods induce significant and undesirable sample loss. 
 
 
Figure 3.3.20 Example of protein melting curves generated using circular dichroism. Each color 
represents the same protein in a different buffer, demonstrating how protein environment can 
affect thermal stability. 
 
The effect of heat on rcPfHRP2-heme binding was also investigated by monitoring the 
CD spectra at different temperatures. Typical proteins with defined structures tend to denature 
and lose those structures with the addition of heat, and protein stability can be affected by 
binding small molecules, thus affecting the denaturation process. Since rcPfHRP2 seems to gain 
structure by binding heme, we wanted to see if heating the complex would disrupt that binding 
and revert the protein structure. CD can be used to find the melting temperature of a protein due 
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to the sharp structural transition in the protein, which is easily visible when monitoring CD 
signal at one wavelength.21 These experiments can also be used to determine if factors such as 
buffer type, salt concentration, and other small molecules affect the thermal stability of the 
protein of interest. For example, Figure 3.320 depicts the same recombinant protein in three 
different buffers subjected to the same temperature scan. The melting point, at roughly the 
halfway point of each transition curve, changes depending on the buffer components and their 
effects on the thermal stability of the protein.   
 
 
Figure 3.4. A) Full CD spectra for ITG rcPfHRP2 at room temperature and 85°C. B) CD signal 
for ITG rcPfHRP2 at 222 nm monitored over a temperature scan from 25°C to 85°C. 
 
To determine the effects of heat on the structure of rcPfHRP2, full CD spectra were taken 
of a sample of ITG rcPfHRP2 without heme at room temperature and at 85°C (Figure 3.4A), to 
determine which wavelength to monitor in a more detailed temperature scan. There was a 
noticeable change in signal intensity at 222 nm, which is also a common wavelength to monitor 
in CD temperature scans, so it was chosen for further study. The protein was then subjected to a 
gradual change in temperature, with CD signal at 222 nm being recorded after every 1°C change 
(Figure 3.4B). This temperature scan showed no sharp melting transition, however, indicating 
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that any structural changes observed by CD in this case are gradual and not the result of large-
scale melting. These experiments were then repeated on rcPfHRP2 samples bound to 15 molar 
equivalents of heme (Figure 3.5). Again, slight difference in CD signal at 222 nm was observed 
when the sample was heated to 85°C, so this wavelength was chosen for gradient monitoring. 
The temperature scan at 222 nm showed more variation in the heme-bound protein than the 
heme-naïve sample, but it still did not contain sharp inflection points indicating a sharp structural 
transition temperature. Both experiments with the heme-bound protein indicate that heat will not 
disrupt the binding of rcPfHRP2 and heme. 
 
 
Figure 3.5. A) Full CD spectra for ITG rcPfHRP2 with 15 molar equivalents heme at room 
temperature and 85°C. B) CD signal for ITG rcPfHRP2 with 15 molar equivalents heme 
monitored at 222 nm over a temperature scan from 25°C to 85°C. 
 
Furthermore, it is worth noting that these structural changes to rcPfHRP2 upon heme 
binding are only observable when an untagged protein variant is used. Many commercially-
available rcPfHRP2 variants, such as that from CTK Biotech and AbD Serotec/Bio-Rad, contain 
either a glutathione transferase (GST) or partial maltose-binding protein (MBP) fusion tag. The 
GST tag is ~26 kDa, which is nearly the same size as the ~30 kDa PfHRP2 portion of the fusion 
protein, and the partial MBP tag is ~ 9 kDa, roughly one-third the size of PfHRP2. When CD 
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spectra are taken of these variants, the mostly a-helical structure of the tag overwhelms the 
spectra, and it is impossible to see any structural changes as the result of heme addition to the 
solution (Figure 3.6). These tags can be cleaved from the protein of interest, but this step also 
requires further column purification which can result in protein loss. 
 
 
Figure 3.6. Heme titrations in phosphate buffer of A) CTK Biotech rcPfHRP2 containing a GST 
tag and B) AbD Serotec rcPfHRP2 containing a partial MBP tag. 
 
 Control experiments replacing heme with Zn(II)PPIX were performed to ensure that 
these structural changes were specific to heme addition. Zn2+ has a well-documented affinity for 
PfHRP2, as it was used in an affinity column format to isolate native PfHRP2 when the protein 
was first identified.22 Furthermore, our lab currently uses Zn2+-conjugated magnetic beads to 
quickly purify PfHRP2 from blood culture samples. Therefore, we decided that using Zn2+ bound 
in the same porphyrin ring as heme would be a suitable control to determine whether the protein 
was interacting solely with the iron center of heme, or if the binding was unique to the larger 
heme molecule. The control CD spectra show no change to rcPfHRP2 structure upon addition of 
Zn(II)PPIX (Figure 3.7A), which means that the structural shifts above are a result of the unique 
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heme binding to the protein. Further control experiments were run by adding 100 mM NaOH 
directly to ITG rcPfHRP2 in PB without heme present to ensure that the spectral changes 
produced above were not the result of protein dilution. As expected, the spectra did not change 
with the addition of NaOH alone (Figure 3.7B).  
 
 
Figure 3.7. Control experiments showing the titration of A) ZnPPIX and B) the same volume of 
100 mM NaOH into ITG rcPfHRP2 in PB. 
  
Effect of heme-protein binding on RDT performance 
 After confirming that heme binds to rcPfHRP2 in a way that alters the three-dimensional 
structure of the protein, we investigated how these changes affect RDT performance with the 
protein. Three different RDT brands were tested using duplicate sample sets of various 
rcPfHRP2 concentrations in PBS. One sample set contained no additional heme, and the other 
sample set was pre-incubated with 10.64 molar equivalents of heme relative to the protein 
concentration. For all three RDT brands, a clear drop in signal was observed for those samples 
which were pre-incubated with heme compared to the control samples (Figure 3.8A-C). 
Furthermore, one RDT brand was tested with varying levels of heme pre-incubated with samples 
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of one rcPfHRP2 concentration (Figure 3.8D). These experiments show a steady drop in RDT 
signal with increasing heme equivalents added to the protein sample. These results indicate that 
the change in rcPfHRP2 structure caused by heme binding can affect the protein’s ability to bind 
to antibodies on RDTs. Because all heme levels tested in Figure 3.8 were below the saturation 
level of 15 equivalents relative to protein, we can assume that most of the heme added to these 
samples was bound by the protein and was not free in solution to disrupt the antibody binding in 
other ways.  
 
 
Figure 3.8. Effect of heme binding on rcPfHRP2 RDT signal for A) Paracheck-Pf RDTs, B) SD 
Bioline Malaria Ag Pf RDTS, and C) ICT Malaria Pf RDTs. D) Varying heme concentration with 
constant rcPfHRP2 on SD Bioline Malaria Ag Pf RDTs. 
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 The protein concentrations used in these experiments would correspond to the protein 
levels found in malaria patients with high parasitemia loads, based on ELISA quantification of 
PfHRP2 found in our in-lab parasite culture. Similarly, the corresponding heme concentrations 
tested are within the typical range for free heme in parasitized blood samples, as quantified by 
past lab members. However, it is important to note that we do not observe these drastic signal 
differences when rcPfHRP2 is spiked into whole blood, and we do not expect such a large heme-
binding effect in native parasitized samples. This is because blood contains several other heme-
binding proteins, such as human serum albumin (HSA)23, which will bind some percentage of 
free heme in blood, making it unavailable for binding with PfHRP2. However, it is still possible 
for free heme to bind to PfHRP2 and change its structure, thus interfering with antibody-based 
detection assays such as RDTs. Diagnostic tests run on patients with high levels of circulating 
PfHRP2 and some amount of heme binding interference would probably still yield a positive 
result. For patients with low parasitemia loads and low circulating PfHRP2 concentrations, even 
a small heme-binding interference could mean the difference between a diagnostic test showing a 
positive or negative result. A false negative from the heme binding interference would lead to 
delayed treatment and potentially a worse outcome for the patient.  
 
Effect of heme-protein binding on ELISA performance 
 An ELISA format was used to further probe the effect of heme-induced structural 
changes on rcPfHRP2-antibody binding. This PfHRP2 ELISA was developed in our lab and is 
quite reliable for recombinant and native protein detection.16 Its performance was re-evaluated 
with ITG rcPfHRP2 in buffer before further experiments were run because we had not previously 
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used the ITG recombinant variant with this assay before. (Figure 3.9A) Of particular interest 
was the dynamic range with this variant, since further experiments would depend on a reliable 
standard curve. Since the standard curve is linear up to 5 pM of ITG rcPfHRP2, three test 
concentrations below this value were chosen to evaluate the effects of heme binding on ELISA 
performance. Samples of 0.5 pM, 1 pM, and 3 pM ITG rcPfHRP2 were incubated with varying 
amounts of heme for 15 minutes before being added to the prepared ELISA plate. Once the 
ELISA was completed, the apparent rcPfHRP2 concentration was calculated for each sample 
using the standard curve. The apparent concentration was compared with the actual known 
protein concentration added to that well to calculate the percentage of protein successfully bound 
to the ELISA antibodies. All protein concentrations tested showed a decrease in ELISA 
performance after incubation with 5 molar equivalents of heme, with only 40 – 50 % of protein 
detected (Figure 3.9B). 
 
 
Figure 3.9. A) ELISA standard curve using ITG rcPfHRP2 as standard antigen and B) Effect of 
heme-rcPfHRP2 binding on ELISA signal for several rcPfHRP2 concentrations and varying 
heme equivalents. 
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 The ELISA format allowed us to probe higher heme concentrations than those used in the 
previous RDT and CD experiments. While a heme:protein ratio of 25:1 or 50:1 is not necessarily 
biologically relevant, it does allow us to understand how the assay performs when there is an 
excess of free heme in solution. RcPfHRP2 is saturated with heme after 15 equivalents have been 
added, and this changes the protein structure so that the apparent concentration detected by 
ELISA is roughly 40% of the actual protein concentration. If more heme is added, however, the 
apparent protein concentration does not continue to drop until 50 molar equivalents of heme have 
been added. This indicates that the heme is probably not interfering directly with the antibodies 
in the assay, only the rcPfHRP2 structure that allows the antibodies to bind to it. 
 Again, such drastic binding interference is not expected in parasitized blood samples, but 
it is more likely that heme binding in blood does dampen the signal of rcPfHRP2 assays to some 
smaller degree. Unfortunately, it is impossible to use CD to investigate native or recombinant 
PfHRP2 in a complex protein-rich matrix such as blood, so a complete picture of heme-induced 
structural changes has not yet been achieved. Future work can instead focus on rcPfHRP2 spiked 
into whole blood, or isolated native PfHRP2. While native protein can be isolated from blood 
using protocols developed in our lab16, it is not to the scale or purity standards that would be 
necessary for CD analysis. 
 
Conclusion 
 This chapter explored the structural changes of rcPfHRP2 when bound to heme and the 
practical effects of these changes on antibody-based assays to detect the protein. Heme binds to 
rcPfHRP2 at a saturating ratio of 15:1, shifting the protein structure from a predominantly 
random-coil form to a helical structure. These structural changes adversely affect rcPfHRP2 
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binding to antibodies in RDT and ELISA formats, and they appear to be reversible with 
diafiltration. Future work depends on the ability to successfully isolate pure native PfHRP2 from 
culture or patient samples, which past lab members have proven is difficult to do at adequate 
purity and scale for these experiments. 
 These results have implications in future assay development. As the community 
continues to develop more and more sensitive diagnostic assays, every possible hindrance must 
be removed, including assay binding interference caused by heme. The sample filtration 
discussed above may be one solution to this issue, but it has not been tested on real-world 
samples. Heme-induced structural changes for rcPfHRP2 may also lead assay developers to 
investigate assays that do not rely on antibody binding, such as the assay described in the 
previous chapter, or to focus on a different biomarker altogether, such as DNA biomarkers 
discussed in later chapters. 
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CHAPTER IV 
 
 
 
DEVELOPMENT OF AUTOMATED DEVICES FOR THE EXTRACTION AND PCR 
AMPLIFICATION OF MALARIA DNA FROM SURROGATE PATIENT SAMPLES 
 
 
 
Introduction 
 
 Current point-of-care diagnostics for malaria rely on the presence of protein biomarkers 
PfHRP2 and Plasmodium lactate dehydrogenase (pLDH) to work effectively. These proteins and 
their unique characteristics offer many advantages in a diagnostic setting, but they are not 
without their faults. For example, pLDH is an essential enzyme produced by all Plasmodium 
parasites, so it is unlikely to suffer gene deletions, and it can be used as a diagnostic in any 
geographic area regardless of the prevalence of particular parasite species.1,2 Furthermore, it does 
not persist in the body after parasites have been cleared, unlike PfHRP2, which can persist for 
weeks even after the patient has been cured.3–6 However, pLDH can be difficult to work with 
because it is easily denatured, and rapid diagnostics tests for the protein are not as sensitive as 
those for PfHRP2.7–9 PfHRP2 is a convenient diagnostic protein for several reasons, including 
those explored in the previous two chapters. Its histidine-rich structure allows for the use of 
metal-based chemistry for both isolation and detection of the protein, and its lack of a defined 
three-dimensional structure makes it very stable at high temperatures, as noted previously in this 
dissertation.10,11 Biologically, the protein persists in patients long after parasite clearance, making 
it a poor biomarker for monitoring treatment effectiveness.3,4,6 It is also a common gene deletion 
in parasites in certain geographical areas, such as South America, making it an unreliable 
biomarker in general.12–14 So, while both PfHRP2 and pLDH have been important biomarkers in 
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the modern fight against malaria, it is clear that we need to incorporate other biomarkers into the 
diagnostic strategy as we move towards malaria elimination. 
 DNA is commonly used as a biomarker for human pathogens due to its versatility and 
specificity. For malaria, the presence of any DNA sequence specific to the parasite in a patient 
sample can be used for diagnosis. DNA can also provide much more information than a positive 
or negative diagnosis. Sequence variation between Plasmodium species can be used to determine 
the particular species infecting the patient, thus informing treatment since different drugs are 
used to treat different species of Plasmodium.8,15,16 Furthermore, genetic information can change 
the treatment between two patients infected with the same Plasmodium species. Mutations in the 
K13 propeller gene in Plasmodium falciparum have been found to lead to artemisinin resistance, 
indicating that identifying only the parasite species may not be enough to effectively treat the 
patient.17,18 DNA also provides practical advantages to protein biomarkers. It is relatively stable 
even at room temperature at basic pH, provided the solution is not contaminated with DNase. 
Specific sequences can be captured from samples simply by using synthetic, cheaply available 
complementary DNA, without the need for expensive, time-consuming antibody production that 
hinders several protein diagnostics.  
 Of course, DNA is not a perfect biomarker for pathogens, and it has drawbacks of its 
own. Specific malaria DNA sequences are often present at much lower concentrations than 
protein biomarkers in patient samples, so a target amplification step is often needed before the 
DNA biomarker can be detected.19,20 The most reliable DNA amplification method is polymerase 
chain reaction (PCR), which requires expensive equipment and reagents and extensively-trained 
technicians to perform.  These requirements make PCR a viable diagnostic technique in modern, 
well-equipped diagnostic labs or hospitals, but they are some of the largest hindrances to the use 
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of DNA as a biomarker in low-resource settings. Furthermore, PCR is often inhibited by 
compounds commonly found in patient samples, such as the hemoglobin in blood.21 This means 
that DNA biomarkers must be extracted from the sample matrix before detection can occur, 
adding another lengthy, manual step to the diagnostic process. Silica-based extraction techniques 
are frequently used to capture all nucleic acids in a sample, but they are most commonly used as 
centrifugal columns which require expensive centrifuges to purify a sample.  
 Silica-functionalized magnetic beads are an attractive alternative to column-based DNA 
extractions because the only additional equipment they require for use is an external magnet. 
Magnetic beads are easy to manipulate manually in small sample tubes with a hand-held magnet, 
or they can also be easily integrated into high-throughput automated extraction devices.22–26 
These devices are typically well plate- or chip-based, and they use an external magnet to either 
keep the beads stationary within a plate or move the beads through an array of processing 
solutions. Plate-based devices require complex fluid pumping and movable robotics, and are 
forced by design into batch-based processing.22 In this device design, multiple samples are 
processed in parallel on a plate, and an entire plate is usually filled before processing. These 
systems work very well in high-throughput laboratories, but they are inefficient in low sample 
number settings. Magnetic beads have been used in chip devices to eliminate the need for fluid 
pumping, but the format requires multiple solution outlets and precise fluid manipulations.26 An 
ideal DNA extraction device for a low-resource setting would not require complex fluidics or 
robotics, but would instead consist of a simple, flexible design made of components that are both 
easy to program and easy to repair. 
This chapter describes the development of a magnetic bead-based protocol to extract 
malaria DNA from blood, and its adaptation into two automated devices that can be used to 
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simplify the extraction and detection workflow. The first roller-based device requires offline 
PCR analysis, but the second axle-based device incorporates PCR thermocycling as the final 
step. The first device (Figure 4.1A) consists of a circular plastic cartridge that rests on both a 
roller controlled by a programmable motor, and a support bar containing six neodymium 
magnets. To perform an extraction, the sample is incubated with magnetic beads to capture the 
biomarker of interest, and then it is then loaded into a length of small-diameter plastic tubing 
containing preloaded processing solutions. This length of tubing is wrapped around the device 
cartridge and as the cartridge rotates, the biomarker-bound magnetic beads are transferred 
through the processing solutions by the stationary external magnet. Biomarker extraction in this 
format is enabled by our previously described surface tension valves, or immiscible fluid 
separators, which are used to sequentially array processing solutions within a single length of 
small-diameter tubing.10,27–29 The second device follows a similar design, but with a cassette fixed 
on a central rotation axle (Figure 4.1B). This design also allows us to incorporate the electronics 
necessary for PCR thermocycling and optical detection in-tube directly after DNA extraction. 
This simple format for both of these devices has advantages over other biomarker 
extraction procedures because multiple biomarker classes can be extracted on the same device, 
simply by using different bead surface chemistries and processing solutions. The devices require 
little power and are simple to operate. The performance of these devices were validated for the 
extraction of malaria DNA using a panel of surrogate patient samples prepared by the Program 
for Appropriate Technology in Health (PATH).  
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Figure 4.1. A) Roller-based automated biomarker extraction device, which requires off-line PCR 
analysis. B) Axle-based automated biomarker extraction and detection device, which includes 
heating and optical detection elements allowing the user to run PCR in the same extraction tube 
directly after DNA extraction. 
 
Materials and Methods 
Materials for DNA biomarker extraction tube 
 Plasmodium falciparum (malaria parasite) infected sample panels were prepared and 
provided by PATH. Primers, probes, and reference standard templates were purchased from 
Integrated DNA Technologies. SuperScript III RT/Platinum TAQ mix (Cat # 11732-088) and 
Dynabeads MyOne Silane magnetic beads (Cat # 37002D) were purchased from Life 
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Technologies. Quanta PerfectA 2x mastermix was purchased from VWR (Quanta Biosciences, 
Cat # 84010). Filtration swabs (Cat # 5001.02) were purchased from Salimetrics Inc. Fluorinated 
ethylene propylene (FEP) tubing was purchased from McMaster Carr (Cat # 2129T11 and # 
9369T46). Hemato-Seal tube sealing compound (Cat # 02-678) was purchased from Fisher 
Scientific. All other materials and reagents were purchased from Sigma Aldrich or Fisher 
Scientific.  
 
Materials for roller-based device fabrication 
The Arduino UNO Rev3 programmable controller was purchased from Arduino (Cat # 
A000066). The stepper motor drive controller (Cat # STR4), stepper motor (Cat # HT23-401), 
and power supply (Cat # PS150A24) were purchased from Applied Motion Products. Cylindrical 
magnets were purchased from SuperMagnetMan (Cat # Cyl0360 N40). The components were 
assembled using aluminum components made in-house by the Vanderbilt Physics and 
Astronomy Machine Shop. The plastic cassettes were designed and printed in-house using 
SolidWorks software and a NovaCopy ProJet HD 3000 Plus 3D printer.  
 
Design and operation of the roller-based automated biomarker extraction device 
 The automated biomarker extraction device was designed to transport magnetic beads 
through a series of processing solutions contained within 1.6 mm i.d. tubing by rotating an 
extraction cassette (i.e., a plastic disc with extraction tubing wrapped around the circumference) 
past a fixed magnet using a simple stepper motor (Figure 4.1A). The cassette is a plastic disc 
that is 14 cm in diameter and 1.9 cm thick, with a continuous channel on the outer edge to secure 
the assay tubing around the disc circumference. In this design, individual cassettes are placed 
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onto a rotating shaft to drive the rotation of the cassettes past a second shaft containing fixed 
magnets. As the disc rotates, the magnetic beads within the assay tubing are held in place by the 
magnets while the processing solutions contained in the assay tubing move past the beads. An 
open-top roller-drive design was chosen over an axle-drive design to facilitate asynchronous, 
random-access loading and processing of independent cassettes on the device.  
 The Arduino UNO Rev3 programmable controller was used to send logical input 
commands to the motor controller to regulate the direction, speed, and timing of the drive motor. 
The Arduino code was developed to allow the operator to input desired rotational distance and 
velocity. Two timing gears and a ribbed belt attach the motor to a roller on which the cassettes 
sit. As the roller rotates, friction between the roller and the cassettes causes the cassettes to rotate 
past the panel of fixed magnets. The rotation processes magnetic beads through the array of 
solutions within the tubing.  
 
Materials for axle-based device fabrication 
The Arduino UNO Rev3 programmable controller was purchased from Arduino (Cat # 
A000066). The stepper motor drive controller (Cat # STR4), stepper motor (Cat # HT23-401), 
and power supply (Cat # PS150A24) were purchased from Applied Motion Products. Cubic 
magnets were purchased from SuperMagnetMan (Cat # Cyl0360 N40). The Qiagen ESELog 
USB Fluorescence reader (Cat # 9002069) was purchased from Qiagen. The Peltier heating 
element (Cat # VT-31-1.0-1.3) was purchased from TE Technology. The TDK Lambda Z+ 
Power Supply (Cat # Z36-6-U) was purchased from TDK Lambda. The Omega TC, K-type small 
gauge 0.05” thermocouple (Cat # 5TC-TT-K-36-36) was purchased from Omega. The 
components were assembled using aluminum components made in-house by the Vanderbilt 
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Physics and Astronomy Machine Shop. The plastic cassettes were designed and printed in-house 
using SolidWorks software and a NovaCopy ProJet HD 3000 Plus 3D printer. 
 
Design and operation of the axle-based automated biomarker extraction device 
 As in the device described above, the axle-based extraction device was designed to 
transport magnetic beads through a series of processing solutions contained within 1.6 mm inner 
diameter (ID) tubing by rotating an extraction cartridge past a fixed magnet using a simple 
stepper motor (Figure 4.1B). The cartridge is 3D printed in ABS-equivalent plastic with a 
diameter of 7 inches. The cartridge has a cut-out to allow it to fit onto an axle to enable top-down 
loading onto the axle, and a continuous channel on the outer edge to secure the assay tubing 
around the cartridge circumference. The cartridge contains a copper tube (7.525 mm ID, ½- 
inch long) into which the end of the assay tube is threaded where the detection chamber is 
located. Once the cartridge is loaded onto the axle, this copper tube interfaces with the Peltier 
device to provide a uniform thermal distribution around the circumference of the amplification 
chamber in the assay tube during PCR. Another identical copper tube is located beneath the other 
one into which a 1-inch long FEP tube is inserted that contains water and is capped at both ends. 
This “witness tube” interfaces the same Peltier device when the cartridge is loaded on the 
instrument. A resistance temperature detector (RTD) is contained within the witness tube and is 
connected to the temperature controller to enable monitoring of the fluid temperature. By 
monitoring the temperature of the witness tube, the temperature of the fluid in the assay tube can 
be estimated for temperature feedback and control purposes without having to directly access the 
fluid in the assay tube. The magnet is encased in a spring-loaded plastic holder which maintains 
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constant pressure between the magnet and the assay tube when the cartridge is fitted onto the 
axle. 
 The Arduino UNO Rev3 programmable controller is used to send logical input 
commands to the motor controller to regulate the direction, speed, and timing of the drive motor. 
The Arduino code was developed to require minimal input from the user, so that the cartridge 
always starts the program in the same position. The motor drives the axle, and the rotation 
processes magnetic beads through the array of solutions within the tubing, depositing the beads 
in the PCR solution and pulling them back out after a short elution time. Once the extraction 
portion of the assay is complete, the instrument begins PCR thermocycling. The Peltier heats the 
solutions until the witness tube registers 95 °C, and then it switches off and allows the witness 
tube and assay tube to cool down to 56 °C, when it begins heating again. This is repeated for 45 
cycles, or the operator can stop the reaction early. At the end of each cycle, when the witness 
tube temperature reads 56 °C, the Qiagen fluorescence detector reads the EvaGreen fluorescence. 
 
Nucleic acid quantification by qPCR 
Nucleic acids extracted from the PATH panel samples were quantified by qPCR as 
appropriate according to protocols adapted by PATH from an existing study.30 The primer/probe 
sequences and cycling conditions are provided in Table 4.1. DNA from malaria parasite was 
amplified via qPCR using Quanta PerfectA 2x mastermix in 25 μL reaction volumes. Final 
primer concentration was 800 nM for each primer and final probe concentration was 150 nM. 
For quantification, each reaction was performed in parallel with a standard curve prepared by 
serially diluting synthetic DNA amplicons in TE buffer. The sequence of the amplified gene was 
purchased from Integrated DNA Technologies (IDT). Ten-fold dilutions were prepared from 107 
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copies/μL to 10 copies/μL. No template controls (NTC) were also performed with no DNA 
added. Thermal cycling was performed using the Roche LightCycler 96, and cycle threshold (Ct) 
values were calculated using the provided software.  
 
Table 4.1. Primer and probe sequences for PCR of extracted P. falciparum DNA. The probe is 
only used for off-line PCR after manual on roller-based device extraction, as the in-tube PCR 
uses EvaGreen dye for detection. 
Forward Primer 5’ – ACA TGG CTA TGA CGG GTA ACG – 3’ 
Reverse Primer 5’ – TGC CTT CCT TAG ATG TGG TAG CTA – 3’ 
Probe 5’ – FAM-TCA GGC TCC CTC TCC GGA ATC GA-BHQ1 – 3’ 
Biomarker Template 
5’ – ACA TGG CTA TGA CGG GTA ACG GGG AAT TAG AGT 
TCG ATT CCG GAG AGG GAG CCT GAG AAA TAG CTA 
CCA CAT CTA AGG AAG GCA – 3’ 
 
Manual and roller-based extraction of Plasmodium falciparum DNA from human blood culture 
For manual and roller-based device extractions, assay tubing was prepared in a 43 cm 
length of 2.36 mm i.d. FEP tubing.  The tubing was loaded by pipetting 50 µL elution buffer (10 
mM Tris pH 8.0, 1 mM EDTA, 0.05% Tween-20), 300 µL 70% ethanol, and 300 µL chaotropic 
wash buffer (80% ethanol, 640 mM guanidine thiocyanate, 1.6 mM Tris pH 8.0, 160 µM EDTA, 
0.08% Triton X-100) into one end.  Each solution was separated from the next by a ~6 mm air 
valve.   
A 100 µL sample of malaria parasite-infected human blood culture (5% hematocrit) or 
pooled whole blood spiked with synthetic DNA was combined with 300 µL lysis buffer (4 M 
guanidine thiocyanate, 10 mM Tris HCl pH 8.0, 1 mM EDTA, 0.5% Triton X-100) and 
incubated at room temperature for 10 minutes with occasional vortexing to lyse red blood cells.  
The lysed samples were then filtered using one-fourth of a Salimetrics swab, and the sample was 
expressed from the swab by using a 5 mL plastic syringe. After the addition of 100 µL of 100% 
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isopropanol and 7.5 x 108 silica-coated magnetic beads (25 µL suspension) to the filtered sample, 
it was incubated for 3 minutes at room temperature. Following nucleic acid adsorption, the tube 
contents were pipetted into the end of the preloaded tubing, both ends were sealed with tube 
sealing compound, and the assay was completed using both a manual magnetic bead-based 
extraction method and the two-speed automated extraction method.  
For manual processing, the beads were collected within the sample chamber using a 1-
inch neodymium magnet. The beads were slowly pulled across the air valve into the first wash 
chamber. The magnet was moved back and forth quickly along the wall of the tubing to mix the 
beads within the first wash chamber for 30 seconds. The beads were then pulled into the second 
wash chamber and mixed the same way for 30 seconds. Finally, the beads were pulled into the 
elution chamber, where they were mixed for 3 minutes using the magnet. The beads were then 
removed from the elution chamber, and the DNA in the final solution was quantified by qPCR as 
described above. 
For automated processing on the roller-based device, the tubing was loaded on the 
extraction cassette, and extraction was carried out as described above. After 5 minutes of 
automated extraction, the tubing was removed from the cassette and the DNA in the final 
solution was quantified by qPCR as described above.  
 
Axle-based extraction of Plasmodium falciparum DNA from human blood culture 
For the axle-based device, extraction tubing was prepared in the same way as above, but 
omitting the 50 µL elution buffer. The sample was then prepared and mixed with silane magnetic 
beads as above, and pipetted into the upstream end of the preloaded tubing. Next, 20 µL PCR-
grade mineral oil was pipetted into the downstream end of the tube, leaving a 6 mm air valve 
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between the oil and 70% ethanol wash. The oil was followed with 50 µL PCR reaction mix 
(Table 4.2) pipetted into the downstream end, with no air gap between the oil and PCR mix. The 
downstream end of the tubing was sealed with a Teflon tape-wrapped polypropylene screw, so 
that the screw was in contact with the edge of the PCR solution. The upstream end of the tubing 
was sealed with Hemato-Seal Capillary Tube Sealant.  
 
Table 4.2. Components of the in-tube PCR reaction and their concentrations. 
Component Volume per 50 µL reaction Final Concentration 
5X KAPA2G Buffer 10 µL 1X 
MgCl2 (25 mM) 3 µL 1.5 mM 
dNTP mix (10 mM each) 1 µL 200 µM 
Forward primer (10 µM) 2 µL 400 nM 
Reverse primer (10 µM) 2 µL 400 nM 
KAPA2G polymerase (5 units/µL) 0.5 µL 2.5 units/reaction 
EvaGreen (20 mM) 2 µL 800 µM 
PCR grade water 29.5 µL - 
 
Witness tube preparation 
 A 30 mm length of FEP tubing was cut to make a “witness” tube for temperature 
calibration. This tube was loaded with 20 µL PCR-grade mineral oil and 50 µL water to mimic 
the PCR chamber of the actual assay tube. This witness tube was also sealed with a Teflon tape-
wrapped polypropylene screw and sealant clay to mimic the assay tube. The witness tube was 
inspected before every PCR run to ensure the integrity of the chambers, and replaced if needed.  
 
Loading the tubes onto the axle-based device 
 The witness tube was loaded into the inner groove of the copper heat block, and a 
thermocouple plugged into the instrument was threaded through the clay sealant and submerged 
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in the water chamber to report the temperature to the instrument. The PCR assay tube was loaded 
onto the instrument by threading the upstream (clay-sealed) end through the outer groove of the 
copper heat block, and pulling the tubing through the copper block until the polypropylene screw 
stopped it. This places the PCR solution inside the copper heating block. The tubing was then 
pressed snugly into the groove around the diameter of the cassette. 
 
Validation using surrogate patient sample panels from PATH 
The efficacy of the roller-based and axle-based extraction devices were tested using a 
panel of surrogate malaria patient samples prepared and validated by PATH. Each panel 
contained human blood culture spiked with concentrations of parasite corresponding to a 
biologically relevant low, medium, or high level of infection, or 0.001%, 1%, and 5% 
parasitemia respectively. Negative control samples containing no pathogen were also provided. 
The sample panels tested are listed in Table 4.3. The sample panel was received frozen on dry 
ice and stored at -80 °C until used.  
 
Table 4.3. Detailed composition of mock patient sample panel, diluted from high-parasitemia 
culture with normal blood diluted to a similar red blood cell concentration. All final samples are 
5% hematocrit and stabilized with Glycerolyte 57. 
Spike % Parasitemia Infected cells/µL 
High 5 % 6 - 9 x 104 
Medium 1 % 0.8 - 2.5 x 104 
Low 0.001% 8 - 20 
Negative 0 0 
 
Data analysis for the axle-based device 
 The axle-based extraction and PCR device does not have data analysis software, so a 
manual method of determining cycle thresholds for validation was needed. During the 
 68 
amplification reaction, fluorescence was recorded after each cycle when the witness tube 
temperature reached 56°C. This fluorescence vs. cycle data was recorded and plotted as an 
amplification curve. The first ten cycles of each run were averaged to obtain the background 
signal, which was then subtracted from the raw fluorescence readings. Cycle threshold (Ct) 
values were defined as the cycle when the slope of the measured fluorescence (dF/dCycle) 
reached its maximum.31 
 
Results and Discussion 
Manual extraction optimization 
Before this work was undertaken, our laboratory had used functionalized magnetic beads 
to isolate nucleic acids from sample matrices such as urine,28 synthetic sputum,32 and nasal 
swabs,27 but not blood. The malaria biomarker PfHRP2 had been isolated from blood using 
magnetic beads,10 but it was clear that nucleic acids were quickly becoming a preferred 
biomarker for malaria diagnosis for the reasons explained above. Therefore, a new nucleic acid 
extraction protocol was developed for silane-coated beads that would allow DNA to be extracted 
from blood samples. 
Studies first focused on optimizing the lysis and wash conditions to maximize the 
extraction efficiency of malaria DNA from whole blood. Preferred lysis conditions would not 
require the use of unnecessary PCR inhibitors, extensive heating, or long incubation times. 
Typical silica-based DNA extraction kits utilize proteinase K for lysis, but this enzyme requires 
heating for optimal activity, so it was eliminated after preliminary tests showed a negligible 
effect on extraction efficiency. Triton X-100 was chosen as a lysis detergent instead of sodium 
dodecyl sulfate (SDS) because it is not a PCR inhibitor like SDS. Finally, guanidinium 
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thiocyanate (GuSCN) served to denature proteins and to act as a chaotropic agent to drive DNA 
adsorption to the silica-coated beads. In order to determine the efficacy of these lysis conditions, 
they were tested using the extraction cassette described above using in-house 5% parasitemia 
culture, and subsequently analyzed via qPCR. A high level of parasite DNA (1.26 x 106 
copies/µL) was detected after extraction, which indicated that the parasites were effectively lysed 
using the lysis buffer. 
In order to calculate actual extraction efficiency, the synthetic parasite DNA sequence to 
be amplified was spiked into whole blood at a concentration of 1 x 104 copies/µL and subjected 
to several optimization experiments. First, an effective post-lysis, pre-silica adsorption filtration 
method needed to be identified in order to reduce later bead aggregation due to cell debris from 
the sample. Glass wool is typically an effective blood filtration material,10 but it was not an 
option since the silica surface would bind the parasite DNA before it reached the magnetic beads. 
Instead, a polymer saliva collection swab in a 5 mL plastic syringe was used to filter lysed blood 
samples before introducing the silica-coated magnetic beads. This filtration method resulted in 
an increase in extraction efficiency from unfiltered samples and an increase in ease of bead 
handling due to lack of cell debris (Figure 4.2A).  
Further extraction optimization was performed on filtered samples by adding either a 
second chaotropic wash step to remove excess protein, a second ethanol wash step to remove 
PCR inhibitors, or by increasing the elution volume to ensure that all DNA was being eluted 
from the beads (Figure 4.2B). Percent recovery of spiked DNA was very low for all methods, 
but was not unexpected. Silica adsorption isolates all nucleic acids from a sample, and whole 
blood contains human DNA from the white blood cells. This means that the spiked parasite DNA 
makes up a small percentage of total nucleic acids present in the blood sample, and it is likewise 
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only a small percentage of the nucleic acids bound to the beads. These three optimization tests 
did not increase extraction efficiency, so the original extraction device design was used to extract 
the samples provided by PATH. 
 
 
Figure 4.2. Optimization of DNA extraction cassette. A) Recovery of DNA for unfiltered and 
filtered samples. B) Recovery of DNA for typical cassette design (1 wash each type, 50 µL 
elution) compared to other designs. 
 
As a way to validate our tubing-based extraction method with standard samples, we 
extracted DNA from parasite culture samples provided by PATH for this purpose. These samples 
contained 5% hematocrit in growth media, with standardized parasitemia levels of 0.001%, 1%, 
and 5%, along with uninfected samples. These percentages corresponded to 8 – 20 parasites/µL, 
0.8 – 2.5 x 104 parasites/µL, and 6 – 9 x 104 parasites/µL, respectively, according to the provided 
sample descriptions. All sample concentrations were extracted with our manual method using n = 
9 extractions per concentration. qPCR amplification and detection showed that P. falciparum 
DNA is present at detectable levels after extraction with the manual extraction device, even in 
low parasitemia infections with 8 – 20 parasites/µL (Figure 4.3, black bars). Positive signal was 
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obtained for negative samples, which indicates contamination either during the off-line PCR or 
during the tubing preparation.  
 
 
Figure 4.3. Panel sample DNA extractions using the manual method and roller-based device, 
with off-line PCR run in a LightCycler 96. 
 
Roller-based device validation 
The extraction works well in a manual format, but it is not well-suited to a low-resource 
environment due to the careful handling and manipulation required to successfully operate the 
device. Training and practice are necessary to extract malaria DNA using this extraction tubing 
setup, and it is difficult to handle more than three extraction tubes at one time if one is extracting 
multiple samples. For these reasons, we decided to adapt the handheld extraction tube into an 
automated extraction device that still adhered to parameters required in a low-resource setting, 
namely that it be simple to operate and require little electrical power. The roller-based device 
developed for this purpose features an asynchronous sample loading design that allows for 
samples to be added to and removed from the device at any time while it is running. This is 
particularly appealing in settings that receive low sample numbers, as it removes the requirement 
to batch samples. Users can add or remove individual assay cartridges from the device 
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asynchronously, without stopping or otherwise impacting the processing of other assays. To 
operate the device, the user wraps the cassette around the circumference of a plastic disc, which 
is then placed onto the rollers. The magnetic beads within the cassette are pulled through the 
extraction tubing as the plastic disc rotates past a fixed external magnet (Figure 4.1A). The 
device was programmed with two “steps,” using the first step to slowly pull the beads a short 
distance within the cassette and the second step to quickly rotate the cassette 705° before 
stopping, collecting the beads, and repeating the two steps. The quick rotation step serves to 
spread and mix the beads throughout the chamber in which they are contained, thus washing the 
beads within the wash solutions and elution chamber.  
We used the roller-based device to repeat the DNA extractions above, using the same 
PATH panel samples so that we could compare the roller-based extraction device with a manual 
extraction. All sample concentrations from PATH were extracted with n = 9 per concentration as 
before, and analyzed using offline qPCR after the purified sample was excised from the 
extraction tubing. In general, the automated device recovered only slightly less P. falciparum 
DNA than the manual method, but the DNA was still detected at acceptable levels using qPCR 
(Figure 4.3, gray bars). These results indicated that this automated DNA extraction device could 
be further extended to incorporate PCR, thus resulting in a fully automated sample-to-answer 
diagnostic instrument. 
 
Axle-based device PCR optimization 
Adding PCR to the automated extraction device required adding a chamber to the 
extraction tubing set-up, changing or adding several mechanical elements of the instrument, and 
changing the PCR chemistry. First, the extraction tubing would now contain a PCR reaction 
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mixture as the final chamber (Figure 4.4A), instead of a buffer elution chamber (Figure 4.4B). 
This would allow the DNA to elute from the beads directly into the PCR reaction mixture. The  
removable plastic disc of the previous automated device became a fixed component of the 
instrument, and it was powered by an axle through the center of the disc instead of resting on 
rollers. These changes enabled the addition of a heat block to the disc and an LED fluorimeter to 
the instrument, both of which would be difficult or impossible to incorporate using the 
removable plastic disc from the roller-based device. The reaction temperature was monitored 
using a “witness tube,” or a short piece of tubing containing water and oil to mimic the PCR 
chamber, placed directly beside the reaction tube in the heating block. The temperature of the 
water was monitored using a wire thermocouple threaded through the sealing clay and 
submerged in the water. By design, thermocycling on the axle-based device would proceed by 
heating the copper heat block until the reaction mixture reached 95°C, then passive cooling 
would be used to bring the reaction temperature down to 56°C. Modern PCR instruments hold 
these reaction temperatures for a set amount of time, typically from 30 to 60 seconds. In an effort  
 
Figure 4.4 Final tubing arrays for use with A) the manual extraction method and roller-based 
extraction device, and B) the axle-based extraction device with PCR. 
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to save reaction time and to make the device simpler to program, however, we chose not to 
incorporate “hold” times into our instrument. This meant that the PCR chemistry of our all-in-
one assay had to change from the assay previously used above. 
The new in-line PCR assay was optimized to allow for 1 second hold times at each 
thermocycling step by using the same PCR primers and biomarker targets as above, but using a 
different polymerase specifically suited to fast cycling times. Several polymerases claiming to 
allow fast cycling were tested in a RotorGeneQ PCR instrument, first using typical cycling hold 
times of 30 and 60 seconds for the 95°C and 56°C steps, respectively. When these hold times 
were gradually shortened to 15 and 30 seconds each, then 5 and 10 seconds each, then 1 second 
each, the only polymerase able to amplify the DNA was KAPA2G Fast polymerase (Figure 4.5). 
This polymerase was used in all subsequent axle-based device experiments, and the in-line PCR 
portion of the assay only takes 15 minutes. 
 
 
Figure 4.5. Parasite DNA qPCR standard curve using KAPA2G Fast polymerase with 
progressively shorter cycling hold times. 
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Another crucial consideration for in-line PCR was to prevent the PCR reaction mixture 
from evaporating within the tubing. The extraction tubing chambers are separated by short 
volumes of air, and applying heat to the PCR chamber caused the reaction mixture to evaporate 
and then condense in the air valve nearest to the chamber. To avoid this problem, the PCR 
reaction mixture was separated from the air valve by mineral oil, and the end of the tubing was 
sealed with a plastic screw directly behind the PCR chamber (Figure 4.4A). At both ends of the 
PCR chamber, extreme care was taken to ensure that no air bubbles were introduced because air 
bubbles expand with heat, interfering with the PCR reaction.  
 
 
Figure 4.6. Panel sample results using the axle-based extraction and PCR device. 
 
Axle-Based Device Validation 
Once the reaction and mechanical parameters were worked out, the axle-based design 
was validated using the same PATH panel samples that were used with the roller-based device 
and the manual extractions. The device was able to extract, amplify, and detect Plasmodium 
falciparum DNA from blood culture samples of 5%, 1%, and 0.001% parasitemia with n = 3 for 
each concentration (Figure 4.6). The average Ct values calculated for the positive blood culture 
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samples provided by PATH were statistically significant from one another. However, the Ct 
values for the 0.001% parasitemia and negative samples were not statistically different. This 
result was not surprising when compared with previous results, reported above, that show the 
negative and 0.001% parasitemia samples amplifying with similar Ct values. However, the 
calculated Ct values for these experiments cannot be directly compared to those calculated for 
the roller-based device and the manual extractions, because these Ct values were calculated 
manually without the assistance of LightCycler software and a different polymerase was used.  
The average total time to result for this device, including benchtop preparation steps, was 
85 minutes. If this device were to become publicly available, however, much of the benchtop 
preparation could be eliminated by manufacturing the extraction tubes in bulk. Excluding these 
benchtop steps, the extraction and PCR assay together require 66 minutes on average. In 
  
Figure 4.7. A rendered concept showing the scaled-up axle-based integrated extraction and 
PCR device. A) One axle with 8 cartridges and B) Four axle modules in one instrument. 
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comparison, a typical column-based DNA extraction requires roughly 30 minutes, and the 
original PCR assay in a LightCycler 96 requires roughly 30 minutes to set up and 108 minutes to 
run. This means taking a sample from DNA extraction to PCR detection using typical laboratory 
methods requires a total of 168 minutes, nearly twice the time it takes to achieve the same result 
with our fully integrated device. It is important to note that in its current state, our integrated 
axle-based device can only process one sample at a time, while a typical PCR instrument can 
amplify 96 samples or more at one time. However, our current device is a prototype which can 
be scaled up to process many samples at once by placing multiple cartridges on one axle, and 
controlling several axles with one instrument (Figure 4.7).  
 
Conclusion 
 This chapter has covered the development of a bead-based method for extracting malaria 
DNA from blood samples, and the incorporation of PCR detection in-line with the extraction 
process. The final integrated device combines the chemistry of DNA extraction and PCR 
amplification with engineering to operate the device and detect the amplified DNA. The final 
device halves the sample-to-answer time of a typical extraction and PCR process, and is more 
amenable to a low-resource setting than typical PCR. This instrument can distinguish between 
high, medium, and low parasitemia samples, although the negative panel samples do yield 
positive results at times. Further validation using actual clinical samples would be necessary 
before this device could reach market, and this would also help determine a Ct cutoff value for 
calling positive and negative samples.  
 Overall, this device could help make PCR a more accessible technique in low-resource 
areas, but it will still require a certain level of infrastructure support. The instrument does not 
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require high levels of electricity, but it does require electricity. It also requires a data processing 
in its current form. Although software development could make this easier for users to perform, 
it would be very difficult for an untrained clinician to correctly analyze and interpret the data 
without the instrument making the positive or negative call itself. With further development, 
these improvements could be made, but ultimately it is not simple to transfer PCR from a high-
resource laboratory setting to a low-resource rural clinic setting. DNA detection in diagnostics 
has the potential to provide a large amount of clinically relevant information, but other detection 
methods besides PCR must be developed in order to use DNA diagnostics at the point of care. 
The next chapter of this dissertation works towards this goal by describing a PCR-free method to 
amplify DNA so that it can be detected using a rapid diagnostic test. 
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CHAPTER V 
 
 
 
PROGRESS TOWARD THE DEVELOPMENT OF A BIO-BARCODE-BASED RAPID 
DIAGNOSTIC TEST FOR THE DETECTION OF MALARIA DNA 
 
 
 
Introduction 
 As described and demonstrated in the previous chapter, nucleic acid biomarkers have the 
potential to be a superior diagnostic target for malaria when compared to protein biomarkers. 
Parasite-specific DNA is present in any sample containing parasite, since it does not rely on 
complicated expression pathways like protein biomarkers do. Nucleic acid testing for malaria 
can also yield much more information than testing for protein biomarkers. It is possible to design 
assays that detect genetic sequences conserved by all species of malaria, or sequences that are 
specific to one particular species.1–5 Detecting gene deletions and mutations are also important 
for determining drug resistance,6 which can inform treatment and allow for faster patient 
recovery times. All of this genetic information is not only useful on a per-patient basis, but it is 
also useful in larger epidemiological and mapping studies, such as those tracking malaria species 
and drug resistance distributions over large areas. 
 However, the current state of nucleic acid testing is not perfect, and it faces several 
hurdles for malaria diagnostics. The source of these hurdles is the relatively low concentration of 
nucleic acid biomarkers compared to protein biomarkers. While parasites produce protein 
biomarkers such as PfHRP2 throughout their life cycle, DNA biomarkers are limited by the 
amount of genetic material contained in a single parasite which does not increase with time. For 
example, the 18S SSU rRNA gene is commonly detected for malaria diagnostics because there 
are typically 5 or more copies of the gene per parasite. In patients with low parasite levels, such 
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as 100 parasites/µL blood, this equates to ~ 500 copies/µL of the biomarker gene, or 0.83 fM. 
The most reliable way to detect such low concentrations of DNA is to use PCR, such as in the 
previous chapter. However, PCR presents a second hurdle for nucleic acid diagnostics for 
malaria. While there are a variety of well-developed and dependable PCR methods, the 
technique is mostly reserved for diagnosis in a reference lab due to the equipment and skill 
necessary to perform an assay. Until recently, alternative nucleic acid testing strategies for 
malaria had not been explored because PCR was so dependable on its own. This meant that 
nucleic acid testing was reserved for well-equipped laboratories and point-of-care testing was 
limited to protein-based diagnostics.  
However, in the past several years it has become clear that point-of-care testing can 
benefit from the additional diagnostic information and sensitivity that nucleic acid testing can 
provide over protein assays. Some work has focused on translating lab-based DNA detection 
assays to the field. Recently, several alternative assays such as loop-mediated isothermal 
amplification (LAMP) have been developed as a replacement for PCR in order to simplify the 
equipment and technique required.7–9 LAMP is not a perfect substitute for PCR, since it requires 
more primers than PCR, increasing the risk of false positive amplification. However, the 
isothermal capabilities of LAMP make it a good candidate for simple, field-deployable 
instrumentation. For example, PATH has developed a thermos-like device to contain loop-
mediated isothermal amplification (LAMP) reaction tubes, which are heated by an exothermic 
chemical reaction similar to that used to heat military MREs (Meals Ready-to-Eat).10 Other 
efforts have focused on developing a rapid diagnostic test for malaria DNA similar to those used 
for malaria protein biomarkers. However, due to the low abundance of nucleic acid biomarkers 
as described above, many DNA-based RDTs still require some sort of enzymatic amplification, 
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such as LAMP, before the test is run.11–13 Some groups have even integrated the LAMP reaction 
into the RDT design.14 While this design works well, an even better device would eliminate the 
need for an enzymatic reaction to amplify target DNA to detectable levels.  
One possible method for amplifying target DNA without requiring an enzymatic reaction 
is known as the bio-barcode assay. In this assay developed by the Mirkin group,15 target DNA is 
hybridized to a magnetic bead that was pre-functionalized with a short, complementary DNA 
capture oligo. After washing away unbound sample matrix, the bead/target complex is incubated 
with AuNPs pre-functionalized with a “barcode” tag DNA sequence and a different short capture 
oligo sequence that is also complementary to the target DNA. The final complex sandwiches the 
target DNA between the capture magnetic bead and the tagging “barcode” AuNP (Figure 5.1). 
After stringent washing, the barcode DNA is released by dithiothreitol (DTT) or heat and can be 
detected in a number of ways. The barcode DNA sequence provides enzyme-free amplification 
because there are up to 200 barcode sequences per AuNP, so for every one target sequence 
captured there can be 200 barcode sequences detected. While this amplification is not on the 
same scale as PCR or LAMP, it can be enough amplification to make the change from a negative 
to a positive signal in colorimetric detection assays. 
 
 
Figure 5.1. The bio-barcode assay for DNA detection. This assay was originally used for the 
detection of proteins using antibodies to capture the target biomarker but was then adapted for 
DNA using short oligos to capture a target DNA sequence. 
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 Typically, bio-barcode assays have been coupled with scanometric readouts, where the 
released barcode sequences are re-captured onto a glass slide functionalized with spots of 
complementary capture oligo.15,16 Then, AuNPs functionalized with another short complementary 
DNA sequence are added to the slide and allowed to hybridize to the immobilized barcode DNA. 
The AuNPs provide a visible spot on the glass slide, which can be further enhanced by silver 
staining.16 This scanometric detection method is relatively simple to perform in a laboratory 
setting, but it would be difficult to use as a point-of-care diagnostic in a low-resource setting 
because it requires careful manipulation and a controlled-humidity environment to be successful. 
 
 
Figure 5.2. The scanometric detection method for bio-barcode assays compared to the proposed 
RDT detection method. 
 
 Instead of using glass slides to detect the barcode DNA, the bio-barcode assay format 
would combine perfectly with an RDT detection strategy for DNA biomarkers (Figure 5.2). The 
bio-barcode amplification would overcome the hurdle of low target DNA concentrations, while 
the RDT detection strategy would enable point-of-care clinicians to continue using a familiar, 
simple, self-contained diagnostic device. To our knowledge, the bio-barcode assay has not been 
used as an amplification strategy for RDTs before. While the amplification assay will add several 
pre-processing steps to the RDT workflow, our work in the previous chapter17,18 indicates that in 
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the future, these steps could be incorporated into a simple device to reduce the number of 
complicated steps for the clinician. This chapter discusses the efforts towards combining the bio-
barcode assay with a novel DNA barcode-detecting RDT.  
 
Materials and Methods 
Materials and Reagents 
Table 5.1. List of DNA sequences used for the bio-barcode assay and LFA in this chapter. 
Function Name Sequence 
Magnetic bead 
capture Thio-RevFP 5’-CGT TAC CCG TCA TAG CCA TGT T10 -thio -3’ 
Target biomarker PATH sequence 
5’-ACA TGG CTA TGA CGG GTA ACG GGG AAT 
TAG AGT TCG ATT CCG GAG AGG GAG CCT 
GAG AAA TAG CTA CCA CAT CTA AGG AAG 
GCA -3’ 
Amplification 
AuNP capture Thio-RP 
5’-thio- T10 TGC CTT CCT TAG ATG TGG TAG 
CTA -3’ 
Barcode AuNP 
capture Thio-BarP 5’-GCT AGT GAA CAC AGT TGT GT-T10-thio -3’ 
Barcode sequence Barcode 5’-ACA CAA CTG TGT TCA CTA GCG TTG AAC GTG GAT GAA GTT G-3’ 
LFA test line Biotin-BarP 5'-biotin-T10-CAA CTT CAT CCA CGT TCA AC-3’ 
LFA control line Biotin-controlP 5'-ACA CAA CTG TGT TCA CTA GC-A10-Biotin-3' 
 
 
Figure 5.3. Hybridization scheme for the bio-barcode amplification of the target sequence. The 
brown circle represents the magnetic bead, and the pink circle represents the AuNP. 
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Dynabeads M-270 Amine functionalized magnetic beads (Cat # 14307D) and Dynabeads 
MyOne Streptavidin T1 magnetic beads (Cat # 65601) were purchased from ThermoFisher 
Scientific. All DNA sequences were custom ordered from Integrated DNA Technologies (Table 
5.1, Figure 5.3). Sulfo-SMCC, no-weigh format (Cat # 22622) and EZ-Link Maleimide-PEG2-
Biotin (Cat # 21901BID) were purchased from ThermoFisher Scientific. Amicon Ultra 3K 
MWCO filters were purchased from Millipore (Cat # UFC500324). Unconjugated 40 nm gold 
nanoparticles were purchased from Ted Pella (Cat # 15707-5). FF120HP nitrocellulose 
membrane with 10 mil polystyrene backing (Cat # 10547001) and CF7 high-flow wicking pads 
(Cat # 8117-2250) were purchased from Whatman. G041 glass fiber conjugate/sample pads were 
purchased from EMD Millipore (Cat # GFCP 203000). All other buffers and reagents were 
purchased from either Sigma-Aldrich or Fisher Scientific. 
 
Instrumentation 
Absorbance and fluorescence measurements were taken using a Synergy H4 microplate 
reader, using a Take3 micro-volume plate as needed. Lateral flow assay reagents were deposited 
onto test strips using a BioDot AD1520 Aspirate/Dispense platform, and the individual test strips 
were cut using a BioDot CM4000 membrane cutter. RDT signal measurements were taken using 
a Qiagen ESEQuant Lateral Flow Reader.  
 
Reduction of dithiol bonds on thiolated DNA sequences 
 Thiolated DNA was received lyophilized and protected as a dithiol, which had to be 
reduced before use. The dithiol reduction was accomplished by adding 1 mL 100 mM 
dithiothreitol (DTT) in 0.1 M dibasic phosphate, pH 8.3, to each tube of dried DNA. Each tube 
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was vortexed to fully dissolve the DNA pellet and incubated on a rotisserie for 1 hr. The reduced 
thio-DNA was purified using Amicon Ultra 3K MWCO centrifugal filters. 500 µL sample was 
added to each filter, and centrifuged at 14,000 x g for 30 mins. The concentrated sample 
remaining in the filter was then washed twice by the addition of 500 µL TE buffer, pH 8 
followed by centrifugation at 14,000 x g for 30 mins. After the second wash, the filter was 
inverted into a new collection tube and centrifuged at 1,000 x g for 3 mins to collect the purified, 
concentrated thio-DNA. Each aliquot was diluted with 500 µL TE buffer, pH 8, and the 
concentration was determined by the absorbance at 260 nm using a Take3 micro-volume plate in 
a BioTek Synergy H4 plate reader. Purified thio-DNA was stored in small aliquots at -80°C. 
 
Functionalization of amine-coated magnetic beads 
 A 200 µL suspension of Dynabeads M-270 amine magnetic beads were added to a 
microcentrifuge tube and mixed with 1 mL conjugation buffer (100 mM Na-phosphate buffer, 
pH 7.4, 150 mM NaCl, 0.01% Tween-20). The supernatant was removed, and the beads were 
washed again with 1 mL conjugation buffer. After the supernatant was removed, the beads were 
resuspended in 188 µL conjugation buffer. No-weigh sulfo-SMCC was prepared to a final 
concentration of 10 mg/mL according to the manufacturer’s instructions. 12 µL of 10 mg/mL 
sulfo-SMCC was added to each tube of magnetic beads and incubated at room temperature for 
30 mins on rotisserie. The reaction solution was removed from the beads, and the beads were 
washed twice with 500 µL conjugation buffer before being resuspended in the original volume of 
200 µL conjugation buffer. 
 The maleimide-activated beads were then incubated with 2 µL of 176 µM thio-RevFP 
capture oligo for 2 hrs at room temperature on rotisserie. Excess maleimide sites on the beads 
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were then passivated by adding 2 µL of 500 mM cysteine in water to each tube of beads. After 
incubating for 15 mins on rotisserie, the beads were washed three times with 500 µL conjugation 
buffer and resuspended in a final 200 µL volume of conjugation buffer. 
 
Functionalization of streptavidin-coated magnetic beads 
 Thio-RevFP capture oligo was functionalized with a biotin moiety using EZ-Link 
maleimide-PEG2-biotin reagent. First, 200 µL of 176 µM thio-RevFP capture oligo was buffer 
exchanged into PBS, pH 7 using Zeba 7K MWCO Spin Desalting columns according to the 
manufacturer’s instructions. Final DNA recovery was quantified by the absorbance at 260 nm 
using a Take3 micro-volume plate in a BioTek Synergy H4 plate reader. EZ-Link maleimide-
PEG2-biotin was reconstituted according to manufacturer’s instructions to a final concentration 
of 20 mM. 35.2 µL of 20 mM maleimide-PEG2-biotin (>20-fold excess) was added to 200 µL 
thio-RevFP and incubated on rotisserie at room temperature for 2 hrs. Excess maleimide-PEG2-
biotin was removed using Zeba 7K MWCO Spin Desalting columns according to the 
manufacturer’s instructions. Final biotin-thio-RevFP DNA concentration was determined by the 
absorbance at 260 nm using a Take3 micro-volume plate in a BioTek Synergy H4 plate reader. 
Small volume aliquots were stored at -80°C. 
 200 µL Dynabeads MyOne Streptavidin T1 beads were placed in a microcentrifuge tube, 
and washed three times with 1 mL 1X binding and wash buffer (1XBW buffer) (5 mM Tris 
buffer, pH 8, 0.5 mM EDTA, 1M NaCl, 0.1% Tween-20). Beads were resuspended in 800 µL 
1XBW buffer, and 12.8 µL of 125 µM biotin-thioRevFP capture oligo was added to the beads. 
The beads were incubated on a rotisserie at room temperature for 15 mins before being washed 
three times with 1 mL 1XBW buffer and resuspended in 200 µL of 1XBW buffer. Excess 
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streptavidin sites were passivated by adding 8 µL of 1 mg/mL D-biotin to the beads, which were 
then incubated on a rotisserie at room temperature for 15 minutes. The beads were washed three 
times with 200 µL 1XBW buffer and resuspended in a final volume of 200 µL 1XBW buffer. 
 
Magnetic bead biomarker capture optimization 
 The amount of target DNA required to saturate the surface of the DNA-conjugated M-
270 amine beads was determined by incubating 50 µL aliquots of magnetic beads in triplicate 
with 100 µL of various concentrations of FAM-target DNA in conjugation buffer for 1 hr in the 
dark. The supernatant was removed and saved to quantify the amount of unbound FAM-target 
DNA. The beads were washed three times with 100 µL conjugation buffer (100 mM Na-
phosphate buffer, pH 7.4, 150 mM NaCl, 0.01% Tween-20) and resuspended in 100 µL TE + 
0.05% Tween-20 buffer. The bead solution was heated at 95°C for 10 mins with occasional 
vortexing, and the supernatant of eluted FAM-target DNA was removed. The concentrations of 
the unbound and eluted FAM-target DNA were determined by reading FAM fluorescence (lex = 
495 nm, lem = 520 nm) using a Take3 micro-volume plate in a BioTek Synergy H4 microplate 
reader.  
 The time required to maximize target DNA binding to the surface of the beads was 
determined by incubating 20 µL aliquots of DNA-conjugated M-270 amine beads with 100 µL 
of 150 nM FAM-target DNA for various amounts of time. The supernatant was removed and 
saved to quantify the amount of unbound FAM-target DNA. The beads were washed three times 
with 100 µL conjugation buffer (100 mM Na-phosphate buffer, pH 7.4, 150 mM NaCl, 0.01% 
Tween-20) and resuspended in 100 µL TE + 0.05% Tween-20 buffer. The bead solution was 
heated at 95°C for 10 mins with occasional vortexing, and the supernatant of eluted FAM-target 
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DNA was removed. The concentrations of the unbound and eluted FAM-target DNA were 
determined by reading FAM fluorescence (lex = 495 nm, lem = 520 nm) using a Take3 micro-
volume plate in a BioTek Synergy H4 microplate reader.  
  
Barcode gold nanoparticle functionalization 
40 nm citrate-coated gold nanoparticles (AuNPs) were split into 1 mL aliquots. To each 
aliquot, 1 µL Tween-20 was added and vortexed. Each aliquot was brought to a final 
concentration of 0.4 µM thio-barcode primer and 0.004 µM thio-PATH reverse primer. If 
fluorescently-tagged AuNPs were desired, each aliquot was brought to a final concentration of 
0.4 µM FAM-Barcode DNA. For DNA loading quantification, each aliquot was also brought to a 
final concentration of 0.004 µM FAM-PATH DNA. If the AuNPs did not require a fluorescent 
tag, each aliquot was brought to a final concentration of 0.4 µM Barcode DNA. After all DNA 
additions had been made, the AuNPs were left to incubate in the dark on a rotisserie overnight. 
The next day, all aliquots were buffer adjusted to 10 mM Na-phosphate buffer, pH 7. Then all 
aliquots were brought to a concentration of 0.1 M NaCl and allowed to incubate for 3 hrs in the 
dark on a rotisserie. All aliquots were then brought to a concentration of 0.2 M NaCl, and after 
another 3 hr incubation they were brought to a final concentration of 0.3 M NaCl. The AuNPs 
were then allowed to incubate overnight in the dark on a rotisserie. Excess DNA was removed by 
centrifuging the AuNPs at 5,000 x g for 30 mins, after which the supernatant was removed. The 
AuNPs were then washed three times by resuspending the particles in 1 mL of PBS + 0.1% 
Tween-20 (PBST) and centrifuging at 5,000 x g for 30 minutes, removing the supernatant after 
each wash. After the final wash, the particles were resuspended in PBST to the desired volume 
and concentration. 
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LFA gold nanoparticle functionalization  
 Thiolated DNA was reduced, purified, and stored as described above. 40 nm citrate-
coated gold nanoparticles (AuNPs) were split into 1 mL aliquots. To each aliquot, 1 µL Tween-
20 was added and vortexed. Each aliquot was brought to a final concentration of 187 nM thio-
Barcode primer DNA, and was left to incubate on a rotisserie overnight in the dark. The same 
salt-aging and purification procedures were performed as above. After the final wash step, the 
AuNP pellets were resuspended in the residual buffer and combined into one tube. AuNP 
concentration was determined using absorbance at 520 nm, and AuNPs were diluted to a final 
working concentration of 1.5 nM using PBS with 5% BSA, 0.25% Tween-20, and 10% sucrose 
(LFA AuNP buffer). 
 
Quantification of DNA loading on gold nanoparticles 
 A small volume of concentrated FAM-DNA labeled AuNPs was added to a 500 µL 
solution of 0.1 M dithiothreitol (DTT) in 0.1 M dibasic Na-phosphate, pH 8.3, so that the final 
AuNP concentration was 0.15 nM. This solution was incubated in the dark on a rotisserie for at 
least 2 hrs, until the solution changed from pink to clear. The sample was then centrifuged at 
14,000 x g for 30 mins to remove any debris from the solution. FAM fluorescence was measured 
(lex = 495 nm, lem = 520 nm) using a BioTek Synergy H4 microplate reader. Fluorescence was 
compared to a standard curve prepared using the same FAM-labeled DNA sequences in the same 
DTT solution background. DNA loading in strands per nanoparticle was calculated by dividing 
the nanomolar FAM DNA concentration by the AuNP concentration of 0.15 nM. 
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Barcode gold nanoparticle blocking experiments 
Optimal conditions for tagging magnetic bead-bound target DNA with barcode-
conjugated AuNPs were investigated using barcode AuNPs conjugated with FAM-barcode 
DNA. First, 20 µL magnetic beads were incubated with target DNA or blank buffer as described 
above. After 3 washes with PBST, the beads were resuspended in 100 µL blocking buffer and 50 
µL of 250 pM FAM-barcode AuNPs were added to the tube.  Various buffers such as PBST, 
PBST with low salt, PBST with 5% BSA, and PBST with 1 mg/mL salmon sperm DNA were 
tested to block nonspecific binding of the AuNPs to the magnetic beads. The AuNPs were 
incubated for 1 hr with the beads, before the bead-AuNP complex was washed 5 times with 
blocking buffer. The bead-AuNP complex was then resuspended in 50 µL TE buffer + 0.05% 
Tween-20 and heated for 10 mins at 95°C with mixing to ensure complete FAM-barcode elution. 
FAM fluorescence was then measured (lex = 495 nm, lem = 520 nm) using a Take3 micro-
volume plate in a BioTek Synergy H4 microplate reader. 
 
LFA fabrication  
 The BioDot AD1520 Aspirate/Dispense system was used to deposit test and control line 
solutions onto a Whatman FF120HP nitrocellulose membrane with 10 mil polystyrene backing to 
form the LFA. Each solution contained 100 µM biotinylated DNA and 30 µM streptavidin in 
PBS + 0.1% Tween-20, incubated at room temperature for 30 mins before deposition onto the 
LFA membrane. Line solutions were deposited at a speed of 1 µL/cm of nitrocellulose 
membrane, or 40 nL drops deposited continuously at a 400 µm pitch. The membrane was dried 
at 40°C, and was not blocked unless otherwise noted. EMD Millipore GFCP 203000 glass fiber 
conjugate/sample pads were cut into 1.9 cm x 20 cm strips and blocked by immersing in 50 mM 
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borate buffer pH 9 with 1% BSA, 1% polyvinyl pyrrolidinone (PVP), and 0.25% Triton X-100, 
and were dried at 40°C. Whatman CF7 high-flow wicking pads were used without any 
pretreatment. The LFA was assembled by attaching the wicking pad and blocked conjugate pad 
to the opposite ends of the nitrocellulose membrane adhesive backing card (Figure 5.4), making 
sure that each pad overlapped the nitrocellulose membrane. Early experiments were performed 
without the use of a conjugate pad, and for these “half-strips” the backing card meant to hold the 
conjugate pad was cut off so the LFA consisted only of nitrocellulose membrane and wicking 
pad. A CM4000 guillotine membrane cutter was used to cut the assembled LFA into test strips 4 
mm wide. If the test strips were “whole” strips containing a conjugate pad, then 5 µL of 1.5 nM 
(OD 10) LFA AuNPs (or “conjugate”) in LFA AuNP buffer was pipetted onto the middle of the 
conjugate pad and allowed to dry at 37°C for 1 hr. The test strips were then stored in foil 
pouches with desiccant until use.  
 
 
Figure 5.3. Side view of a complete RDT as fabricated in-house. Control and test lines are in 
color for illustration only. 
 
LFA optimization experiments 
 LFA design and running conditions were first optimized using half-strips, which did not 
contain a conjugate pad. For these tests, 5 µL of sample and 5 µL 1.5 nM AuNP conjugate were 
added to either a test tube or a well in a 96-well microplate, and the LFA half-strip was placed 
into the well like a dipstick, with the nitrocellulose membrane contacting the liquid in the well 
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and with the wicking pad up in the air. Once the sample and AuNP conjugate had been wicked 
into the test strip, running buffer was added to the well in 50 µL aliquots as needed. The strips 
were allowed to develop for 20 minutes before being visualized. Experiments with “full” test 
strips were run by pipetting 5 µL of sample onto the spot of dried AuNPs on the conjugate pad, 
along with 50 µL to 100 µL running buffer, as needed. The strips were allowed to develop for 20 
minutes before being visualized. Experiments were run with a variety of sample, running, and 
AuNP buffers to choose the optimal conditions. Positive controls were run using 50 nM barcode 
DNA in buffer as sample, and negative controls were run using blank buffer as sample. Optimal 
conditions were chosen by visual inspection as those which minimized false positives and 
“smearing” of the AuNPs across the test strip, while allowing for strong positive control signal. 
 
Results and Discussion 
Target DNA binding to amine magnetic beads 
 After the amine-coated magnetic beads were functionalized with thio-RevFP capture 
DNA sequence, their binding capabilities were assessed. First, 50 µL of beads were incubated 
with 100 µL of various concentrations of FAM-labeled target DNA (FAM-PATH) for 1 hr with 
mixing in order to determine the maximum amount of target DNA that could be captured by the 
beads. FAM fluorescence of the sample was measured before and after bead incubation, and the 
percent sample captured by the beads was calculated. Above 200 nM target DNA, the percent 
captured by the beads begins to decrease, indicating that above this concentration the beads 
become saturated with target DNA (Figure 5.5A). Next, the kinetics of binding were 
investigated to determine the optimal incubation time for beads in a sample. To conserve beads, 
this experiment was performed using 20 µL of beads incubated at various timepoints with 150 
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nM FAM-target DNA and mixing. Again, FAM fluorescence of the sample was measured before 
and after beads incubation so the percent of sample captured could be calculated. Even with 
continuous mixing of the sample to ensure the beads did not settle, maximum target binding did 
not occur until 1 hr incubation (Figure 5.5B). This is not ideal for the first step of a point-of-care 
assay, especially one that is meant to replace time-consuming PCR. 
 In order to increase the target binding kinetics, we decided to alter the binding buffer 
components. Hybridization rate accelerators such as polyethylene glycol (PEG) and ficoll are 
 
Figure 5.5. Percent target DNA bound to functionalized magnet beads A) after 1 hr with 50 µL 
beads and various starting concentrations of target DNA; B) with 20 µL beads and 150 nM target 
DNA over various incubation times; and C) after 10 mins with 20 µL beads, 150 nM target DNA, 
and various hybridization accelerators in the binding buffer. 
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used in many molecular biology applications to decrease the time needed for DNA 
hybridization.19 These polymers exclude water from solvating the DNA strands, which 
effectively makes it “look” like the single stranded DNA is at a higher concentration than it truly 
is. This effective increase in DNA concentration also increases the hybridization rate. PEG and 
ficoll were tested as hybridization rate accelerators in the binding buffer, along with a higher 
concentration of NaCl to further stabilize DNA duplexes once they were formed on the beads. 
These experiments were performed with 20 µL functionalized beads, 100 µL of 150 nM FAM-
target DNA and a 10 minute incubation time instead of 1 hour. Our results show that increasing 
the concentration of salt alone is enough to increase target binding from 58% to 82% in 10 
minutes, but with high variation (Figure 5.5C). Combining a higher 1M NaCl concentration with 
5% PEG added to the conjugation buffer allowed us to bind 94% of our target DNA in 10 
minutes while also reducing the variability. This conjugation buffer was used in all further 
experiments as the incubation buffer for the bead-target complex. 
 
AuNP incubation optimization 
 Sandwiching captured target DNA with barcode-functionalized AuNPs is a crucial step in 
this assay. However, nonspecific binding of the barcode AuNPs to the magnetic beads quickly 
became a large hurdle to be overcome. Functionalized magnetic beads that were not bound to 
target DNA captured as many barcode AuNPs as magnetic beads that were bound to target DNA. 
This gave the assay a signal to noise ratio of 1, where a positive sample could not be 
distinguished from a negative one. Several blocking conditions were investigated to reduce the 
nonspecific binding of AuNPs to magnetic beads, including conjugation buffer with low salt, 
PBST, BSA, and salmon sperm DNA.  
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 Initial barcode AuNP binding experiments used the same 1 M NaCl, 5% PEG 
conjugation buffer to incubate the AuNPs and beads as was used to capture the target DNA from 
solution. This gave high background signal, but this was not unexpected due to the nature of the 
buffer. Lower salt concentrations were tested to reduce the stability of nonspecific DNA 
hybridization in an effort to reduce the background signal but when this also reduced the positive 
signal when target DNA was introduced (Figure 5.6A). Buffer with 575 mM salt was used going 
forward to test further blocking conditions with 1% BSA or 1 mg/mL salmon sperm DNA. 
Neither incubation buffer produced an acceptable signal to noise ratio (Figure 5.6B). 
 
 
Figure 5.4. FAM-labeled barcode DNA signal after different blocking conditions were used to 
screen nonspecific barcode-AuNP binding to functionalized amine magnetic beads. A) Varying 
NaCl concentration in AuNP incubation and wash buffer; B) The addition of 1% BSA and 
1mg/mL salmon sperm DNA to 575 mM NaCl wash buffer. 
  
Next, streptavidin-coated magnetic beads were used as a base for the assay instead of 
amine-coated magnetic beads, because unbound free amines on the bead surface could have been 
interacting electrostatically with the barcode AuNPs. It is easy to passivate unbound binding sites 
on streptavidin beads with biotin while it is difficult to fully passivate the surface of amine-
coated beads. These beads were tested with both positive and negative samples, incubated with 
barcode AuNPs in PBST, PBST with 5% BSA, and PBST with 1 mg/mL salmon sperm DNA 
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(Figure 5.7A, B, and C). Again, none of these conditions produced any signal to noise ratio to 
be useful, with some even producing no signal relative to pure buffer. Furthermore, several 
concentrations of NaCl in the PBST incubation buffer were tested to find a concentration to 
encourage specific binding (Figure 5.7E), but none of the concentrations tested produced a 
favorable result. To investigate this issue of nonspecific signal further, AuNPs functionalized 
 
Figure 5.7. Several blocking conditions were tested to reduce nonspecific binding of barcode 
AuNPs to streptavidin magnetic beads. A) PBST + 0.1% Tween-20 (PBST); B) PBST + 5% 
BSA; C) PBST + 1 mg/mL salmon sperm DNA. D) T10 AuNPs used in place of barcode 
AuNPs. E) Varying the NaCl concentration in PBST to encourage specific DNA hybridization. 
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solely with short sequences of 10 thymine residues (T10 AuNPs) were tested in this assay 
instead of barcode AuNPs. In this experiment, it appears that T10 AuNPs bind to streptavidin 
magnetic beads only minimally (Figure 5.7D), so the specific DNA sequences used in this assay 
may be to blame for the high background signal and low target signal. In order to mitigate this 
issue, entirely new target sequences will have to be selected. 
 
 LFA optimization 
Table 5.2. Optimized experimental conditions for the lateral flow barcode detection assay. 
  
Lateral flow assay (LFA) components and conditions were optimized empirically to 
obtain the best limit of detection and dynamic range possible. This was achieved by choosing 
conditions that minimized background binding of LFA AuNPs to the nitrocellulose membrane 
while also allowing the assay sandwich to form effectively at the test and control lines. We 
aimed to design a test that would detect barcode DNA that had been eluted into a water and 
Tween-20 solution, preferably only using 5 µL of this eluted sample as this is a typical sample 
Experimental Condition Values tested Optimum value 
LFA AuNP buffer 
PBST; 5% BSA; 0.25% 
Tween-20; Denhardt’s 
solution; 5% BSA, 0.25% 
Tween-20, 10% sucrose 
5% BSA, 0.25% Tween-20, 
10% sucrose 
Nitrocellulose blocking 
None; TBS pH 7.4, 0.015% 
casein, 0.3% PVP, 0.05% 
Tween-20 
No blocking 
Conjugate pad material Whatman glass fiber, Millipore glass fiber Millipore Glass fiber 
Conjugate pad blocking 
None; 50 mM borate buffer 
pH 9, 1% BSA, 1% PVP, 
0.25% Triton X-100 
50 mM borate buffer pH 9, 
1% BSA, 1% PVP, 0.25% 
Triton X-100 
Running buffer ionic strength 4X, 1X, 1/2X, 1/4X SSC 4X 
Running time 10 min, 20 min, 30 min 20 min 
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volume for commercial LFAs. In order to achieve this goal, the use of a conjugate pad was 
required to allow salts and blocking agents to be dried into the pad. If a half-strip (no conjugate 
pad) was used, mixing the water sample with LFA AuNPs in a test well caused the AuNPs to 
aggregate, which causes the test to lose all function. The components optimized for this assay 
were LFA AuNP buffer, nitrocellulose blocking, conjugate pad material, conjugate pad blocking, 
and running buffer composition, as summarized in Table 5.2 above. 
  Once the conditions and parameters for the LFA were optimized, various concentrations 
of barcode DNA were diluted in PBS + 0.5% Tween-20 and run on the test to determine an 
approximate limit of detection (Figure 5.8). The optimized LFA can detect barcode DNA as low 
as 0.156 nM, which in theory would equate to roughly 2x107 barcode AuNPs being pulled 
through the assay to elution. This also equates, in theory, to 2x107 copies of target malaria DNA 
being captured by the magnetic beads. In a 100 µL sample, this would translate to an original 
biomarker concentration of 2x105 copies/µL minimum if all copies of the biomarker are bound 
by the beads. This is a very feasible concentration of this target DNA sequence in a malaria 
sample, corresponding to about 1% parasitemia in standardized cultures. Ideally this LFA would 
Figure 5.5. A) The full binding curve using the optimized LFA to detect barcode DNA in 
buffer B) Zoomed-in binding curve from 0 – 2.5 nM  showing the limit of detection of 0.156 
nM barcode DNA in buffer. 
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be further optimized to further decrease the limit of detection to allow for the diagnosis of lower 
parasitemia patients. 
 
Conclusion 
This assay has produced new knowledge for the laboratory in terms of LFA optimization. 
The LFA for barcode DNA detection is the first full LFA developed in our laboratory, and holds 
great promise for future applications. The detection binding for this LFA is also entirely DNA 
hybridization-based, and therefore eliminates issues associated with antibody stability. If the 
AuNP binding in the bio-barcode assay can be optimized, then the entire bio-barcode-RDT assay 
will be functional as a low-resource method to detect malaria DNA in patient samples. 
Furthermore, any of the DNA sequences can be changed to suit future needs; different biomarker 
sequences for other diseases may be targeted by the capture beads and different sequences can be 
targeted by the LFA. Furthermore, the assay could be multiplexed to detect multiple malaria 
species or multiple diseases by using different barcode sequences for each target. Also, if a 
particular DNA or RNA sequence is present in a sample in high enough abundance, it is possible 
that the current DNA LFA sequences and buffer conditions could be modified to detect that 
biomarker from a patient sample without requiring the bio-barcode portion.  
Furthermore, we have decreased the time it takes to isolate specific sequences of DNA. 
Previous work by our collaborators20 showed that sequence-specific DNA isolation can take up 
to 3 hours to isolate 80% of a sample, making this type of DNA isolate seem unfeasible in a 
diagnostic setting. This work has shown that with the right buffer conditions, DNA can be 
isolated by sequence-specific hybridization in as little as 10 minutes, which opens the door for 
assays such as the bio-barcode assay that do not rely on downstream PCR for target-specific 
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detection. The roadblock of nonspecific AuNP binding still stands, but further work on this assay 
can be performed to minimize this binding.  
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CHAPTER VI 
 
CONCLUSION AND PERSPECTIVES 
 
 This dissertation encompasses work performed in the advancement of both protein- and 
DNA-based malaria diagnostics. As malaria control efforts mature into malaria elimination 
efforts, sensitive and accurate point-of-care diagnostics will be extremely important tools. Most 
current point-of-care diagnostics detect protein biomarkers such as PfHRP2 or pLDH. These 
tests can accurately diagnose symptomatic infections, but become more unreliable at low parasite 
densities, when the patient typically does not present symptoms. These tests can also be degraded 
by heat and humidity because they are antibody-based. As an alternative, the malaria community 
has recently focused its efforts on DNA-based diagnostics that are accessible in a low-resource 
setting. DNA can provide more diagnostically-relevant information than protein, and it is more 
stable than protein in typical working conditions. It can also be amplified using a variety of 
enzymatic reactions, if necessary, although these reactions are often technically demanding and 
not well-suited to low-resource settings. The work presented here sought to improve upon these 
issues with protein and DNA diagnostics in several ways. 
First, a fluorescent detection method for PfHRP2 was described that relies on a transition 
metal compound rather than enzyme-tagged antibodies to produce signal. This system is more 
stable than an antibody-based detection system, and was incorporated into an on-bead sandwich 
assay similar to an ELISA. The on-bead assay work best in a laboratory setting, but it could also 
potentially be incorporated into a field diagnostic for PfHRP2. The “switch-on” fluorescence 
capabilities could be used in conjunction with a UV pen light or a portable fluorimeter to read 
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fluorescence, and the mixing of the iridium reagent and PfHRP2 could be accomplished by any 
number of easy-to-use devices, including a “glow stick” device. In the next chapter, the structure 
of rcPfHRP2 in the presence of heme was investigated using circular dichroism. Heme binding 
causes the protein to adopt a more helical structure than its typical unstructured form, and this 
shift in structure also adversely affects the protein’s ability to bind to antibodies on RDTs and in 
ELISAs. The effects of heme could be further investigated on native PfHRP2 to ensure that these 
results are not unique to the recombinant protein. If they are not replicated by the native protein, 
then this brings up important questions about using recombinant PfHRP2 as a standard in 
diagnostic assays.  
Work then transitioned to focus on DNA-based diagnostics due to the valuable 
information that DNA biomarkers can provide, and the large unmet need for point of care DNA 
diagnostic tests. Because sample preparation can be a bottleneck for DNA diagnostics, initial 
work focused on simplifying the DNA extraction process into an automated format. This device 
was then expanded to include PCR in-line with the extraction to eliminate the manipulation and 
technical difficulties of setting up an external PCR reaction. In a low-resource setting, this would 
allow an unskilled operator to input a raw sample into the device and receive a reliable PCR 
result without performing any technically-demanding procedures. These devices work well, but 
still rely on PCR amplification and data analysis to obtain a result. In the next chapter, a DNA-
based RDT was developed to bring DNA diagnostics to the point of care. The RDT uses DNA 
hybridization to form a “sandwich” similar to a typical antibody-based RDT, which could allow 
the RDT to be customized to detect nearly any sequence of DNA simply by changing the capture 
and detection DNA sequences attached to the RDT membrane and detection AuNPs. This RDT 
was optimized to detect a “barcode” DNA sequence, as part of the bio-barcode assay. The bio-
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barcode assay is a way to amplify target DNA by hybridizing the capture target to a gold 
nanoparticle tagged with hundreds of barcode DNA sequences. When the barcode sequences are 
released, the signal from one target DNA strand is amplified to a level detectable by the RDT. 
The particular bio-barcode assay developed in this chapter has issues with nonspecific binding of 
barcode AuNPs in a negative sample, so unfortunately the two aspects of this assay were never 
combined with good results. However, redesigning the capture sequences to target a different 
malaria DNA sequence may reduce nonspecific binding and increase the signal to noise ratio, 
thus allowing the two aspects of this assay to be combined as a low-resource DNA-based RDT.  
 Overall, this work follows the transition in the malaria diagnostics community from 
protein-based methods to DNA-based methods. Protein still has its uses in RDTs, especially 
because these tests are already familiar to clinicians and are monitored by WHO for quality 
purposes. There is still ongoing research, especially in our research group, to improve upon 
current protein diagnostics and to develop new protein-based assays for the point of care. The 
first half of this dissertation focused on improving protein diagnostics with a new metal-based 
assay and by further understanding the protein biomarker and its structure. However, DNA 
diagnostics can provide a wealth of clinically relevant information, and there is currently a 
shortage of new point-of-care DNA diagnostic techniques. In order to bring the value of DNA 
diagnostics to low-resource settings, the malaria diagnostic community needs to move beyond 
PCR amplification methods and investigate new combinations of techniques to amplify DNA so 
that it can be detected with low-resource, point-of-care technology. The second half of this 
dissertation sought first to make PCR more accessible for low-resource settings, and then sought 
to develop a new assay that could be read using a point-of-care RDT. 
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In the future, our research group will pursue both protein-based and DNA-based 
diagnostics with the ultimate goal of providing user-focused diagnostics to low-resource settings. 
Ultimately, the best diagnostic is one that can be easily used and understood by the person 
administering it. In most of the world, the person administering a diagnostic test is most likely 
not a doctor or even a trained clinic worker, so we seek to develop tests that can be understood 
by laypeople. This requires a long, iterative development process, but I believe our laboratory 
can make great strides in this area. We are focused on user-friendly designs and are willing to 
test devices in the field, then bring them back to Vanderbilt to make changes based on what was 
observed during the field trials, and test them in the field again. We can only effectively 
accomplish our goal by making changes based on data and observations, and we have the 
capacity to do so with our collaborators in Macha, Zambia. It is my hope that the work described 
here will contribute to and act as a stepping stone for future protein-based and DNA-based 
diagnostic assays for malaria. 
The DNA diagnostic work presented here also has applications outside the malaria 
community. DNA-based diagnostics can be used for any pathogenic disease – those caused by 
bacteria, viruses, or other microorganisms. In these cases, the disease-causing agent has its own 
genetic code distinct from the human host, and this genetic material can be detected as a 
biomarker. The presence of certain genetic sequences can confirm disease and also inform 
treatment, making DNA an attractive target for low-resource diagnostics development. This 
means that with effective development, one DNA test format can be applied to a multitude of 
diseases, such as tuberculosis, Zika virus, Ebola, and any type of bacterial infection. Adapting a 
DNA test for a different disease can also be done very quickly, simply by changing the DNA 
sequences in the test to be complementary for a disease-specific target sequence. Some re-
 110 
optimization of the test may be necessary, but all of this could reasonably be accomplished 
within a couple of months. In comparison, developing new antibodies to use in immunoassays 
can take several months to a year, which is less desirable. A fast turnaround time to develop a 
diagnostic assay is especially important for emerging diseases such as Zika and Ebola, due to the 
devastation that can be caused without proper diagnosis and treatment. Due to this versatility of 
DNA diagnostics and the wealth of information they can provide, developing low-resource 
DNA-based tests is of great interest to the greater infectious disease community. The techniques 
used in this work show great promise in this regard, and with further development I hope that we 
can see the widespread use of low-resource DNA tests in the near future. 
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APPENDIX A 
 
SUPPORTING INFORMATION: CHAPTER II 
 
 
 
	
 
Supporting Information Figure II.1. 1H NMR of Ir1. 
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Supporting Information Figure II.2. ESI-MS of Ir1. 
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Supporting Information Figure III.3. Cyclic Voltammetry of Ir1. 
 
 
	
 
Supporting Information Figure II.4. UV-Visible spectrum of 100µM Ir1 in MeOH. 
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Supporting Information Figure II.5. Amino Acid selectivity of 50µM Ir1 with 10µM 
solutions of amino acids in 100mM HEPES buffer with 137 mM NaCl (HBS).  Ala, Asp, 
Cys, Ile, Lys, Phe, Ser, Trp and Val were all negligible.  Histidine is shown as a dashed 
line. 																	
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Supporting Information Figure II.6. Signal intensity of L-His with 50 µM Ir1 as a 
function of concentration of deprotonated histidine at each pH. 
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Supporting Information Figure II.7. Quantum yield of 50 µM Ir1 with 400 µM L-His 
and 100 µM BNT-II in HBS. Quinine sulfate was used as the reference compound 
(F=0.546 in 0.5M H2SO4; lex=366nm). 
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Supporting Information Figure II.8. Signal intensity of tripeptides AHH and HAH with 
50 µM Ir1 in HBS. Tripeptides were allowed to incubated with Ir1 for 10 minutes before 
measuring signal at 510 nm (365 nm ex). SlopeAHH = 456 ± 9. SlopeHAH = 356 ± 19. While 
the two curves are statistically different, this data shows that Ir1 can bind both adjacent 
and split histidine residues within the AHHAHHAAD motif of PfHRP2. 
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Supporting Information Figure II.9. Correlation between relative fluorescence signal 
intensity and concentration of total histidine in BNT-II and rcHRP2 with 50 µM Ir1 in 
HBS. 
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Supporting Information Figure II.10. Visualization of Ir1 signal with 100 µM BNT-II 
bound to the surface of 50 µM NI(II)NTA agarose particles deposited on a glass slide. 
Fluorescence was imaged under fluorescence microscopy (Nikon TE2000U inverted 
fluorescence microscope). 
 
	
 
Supporting Information Figure II.11. Signal generated from 50 µM Ir1 coordinating to 
100 nM rcHRP2 bound to the surface of 50 µm Ni(II)NTA agarose particles over 60 
minutes. 
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Supporting Information Figure II.12. Side by side comparison of the linear range of our 
on-bead Ir1 assay (left graph) and a traditional ELISA (right graph) for the detection of 
PfHRP2. The slope of the line for the on-bead assay and ELISA are 15.93 ± 0.13 and 
0.1502 ± 0.0003, respectively. 
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